STOCK TITAN

[10-Q] BlueLinx Holdings Inc. Quarterly Earnings Report

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
10-Q
Rhea-AI Filing Summary

Kiniksa Pharmaceuticals (KNSA) delivered its first profitable Q2. Net product revenue rose 44% YoY to $156.8 m on continued uptake of ARCALYST, lifting six-month sales 56% to $294.6 m. Cost of goods remained low (Q2 COGS 12% of sales), sustaining an ~88% gross margin.

Operating expenses grew 26% to $136.6 m, driven by collaboration spend linked to Genentech and Huadong agreements, but leverage from higher revenue pushed operating income to $20.2 m (-$0.1 m LY). After $5.0 m tax, Q2 net income reached $17.8 m (diluted EPS $0.23) versus a $3.9 m loss a year ago; six-month net income was $26.4 m.

Liquidity strengthened: cash, cash equivalents and U.S.-Treasury investments increased to $307.8 m (up $64 m since year-end) aided by $50.4 m operating cash flow and a $20 m milestone from Huadong. Total assets stand at $661.1 m with equity of $495.0 m; inventory rose to $53.0 m as the company pre-positions ARCALYST supply ahead of a manufacturing tech-transfer approval.

Strategic updates: 1) Redomiciliation from Bermuda to the U.K. completed in 2024; 2) April 2025 termination of the Huadong mavrilimumab license eliminates up to $576 m of potential milestones; 3) Remaining upside includes $570 m in potential Genentech milestones (vixarelimab) and $50 m in ARCALYST sales milestones from Huadong, plus mid-teens royalty streams.

The company expects current liquidity to fund operations for ≥12 months.

Kiniksa Pharmaceuticals (KNSA) ha registrato il suo primo secondo trimestre in utile. I ricavi netti da prodotti sono aumentati del 44% su base annua, raggiungendo 156,8 milioni di dollari, grazie alla continua crescita delle vendite di ARCALYST, che hanno portato le vendite semestrali a un incremento del 56%, a 294,6 milioni di dollari. Il costo del venduto è rimasto basso (Q2 COGS al 12% delle vendite), mantenendo un margine lordo di circa l'88%.

Le spese operative sono cresciute del 26%, arrivando a 136,6 milioni di dollari, principalmente a causa delle collaborazioni con Genentech e Huadong, ma il maggior fatturato ha permesso di ottenere un reddito operativo di 20,2 milioni di dollari (rispetto a -0,1 milioni nel periodo precedente). Dopo 5,0 milioni di dollari di tasse, il reddito netto del secondo trimestre ha raggiunto 17,8 milioni di dollari (EPS diluito 0,23 dollari) contro una perdita di 3,9 milioni dell’anno precedente; il reddito netto semestrale è stato di 26,4 milioni di dollari.

La liquidità si è rafforzata: la somma di liquidità, equivalenti e investimenti in titoli del Tesoro USA è salita a 307,8 milioni di dollari (in aumento di 64 milioni rispetto alla fine dell’anno), favorita da un flusso di cassa operativo di 50,4 milioni e da un pagamento di 20 milioni di dollari da Huadong. Gli attivi totali ammontano a 661,1 milioni di dollari con un patrimonio netto di 495,0 milioni; l’inventario è salito a 53,0 milioni in vista dell’approvazione del trasferimento tecnologico per la produzione di ARCALYST.

Aggiornamenti strategici: 1) nel 2024 è stata completata la redomiciliazione dalle Bermuda al Regno Unito; 2) la cessazione della licenza Huadong per mavrilimumab ad aprile 2025 elimina fino a 576 milioni di dollari in potenziali milestone; 3) le opportunità residue includono 570 milioni di dollari in potenziali milestone da Genentech (vixarelimab) e 50 milioni in milestone di vendita ARCALYST da Huadong, oltre a royalty a due cifre medie.

L’azienda prevede che la liquidità attuale finanzierà le operazioni per almeno 12 mesi.

Kiniksa Pharmaceuticals (KNSA) registró su primer segundo trimestre rentable. Los ingresos netos por productos aumentaron un 44% interanual hasta 156,8 millones de dólares, impulsados por la creciente adopción de ARCALYST, elevando las ventas semestrales un 56% hasta 294,6 millones de dólares. El costo de bienes vendidos se mantuvo bajo (Q2 COGS 12% de las ventas), sosteniendo un margen bruto de aproximadamente el 88%.

Los gastos operativos crecieron un 26% hasta 136,6 millones de dólares, impulsados por gastos de colaboración vinculados a los acuerdos con Genentech y Huadong, pero el apalancamiento del mayor ingreso llevó el ingreso operativo a 20,2 millones de dólares (frente a -0,1 millones el año anterior). Después de 5,0 millones en impuestos, el ingreso neto del Q2 alcanzó 17,8 millones de dólares (EPS diluido de 0,23 dólares) frente a una pérdida de 3,9 millones hace un año; el ingreso neto semestral fue de 26,4 millones de dólares.

La liquidez se fortaleció: el efectivo, equivalentes y las inversiones en bonos del Tesoro de EE.UU. aumentaron a 307,8 millones de dólares (un aumento de 64 millones desde fin de año), apoyados por un flujo de caja operativo de 50,4 millones y un pago de hito de 20 millones de Huadong. Los activos totales son 661,1 millones con un patrimonio neto de 495,0 millones; el inventario aumentó a 53,0 millones mientras la empresa se prepara para la aprobación de transferencia tecnológica de fabricación de ARCALYST.

Actualizaciones estratégicas: 1) Redomiciliación de Bermuda al Reino Unido completada en 2024; 2) La terminación en abril de 2025 de la licencia de mavrilimumab con Huadong elimina hasta 576 millones en posibles hitos; 3) El potencial restante incluye 570 millones en hitos potenciales de Genentech (vixarelimab) y 50 millones en hitos de ventas de ARCALYST de Huadong, además de flujos de regalías de dos dígitos medios.

La compañía espera que la liquidez actual financie las operaciones por ≥12 meses.

Kiniksa Pharmaceuticals (KNSA)가 첫 수익성 있는 2분기를 기록했습니다. 순제품 매출은 ARCALYST의 지속적인 판매 증가로 전년 대비 44% 상승한 1억 5,680만 달러를 기록했으며, 6개월 매출은 56% 증가한 2억 9,460만 달러에 달했습니다. 매출원가는 낮게 유지되어 (2분기 매출원가가 매출의 12%) 약 88%의 총이익률을 유지했습니다.

영업비용은 Genentech 및 Huadong과의 협력 지출로 인해 26% 증가하여 1억 3,660만 달러에 이르렀으나, 매출 증가에 따른 레버리지 효과로 영업이익은 2,020만 달러를 기록하며 전년 동기 -1만 달러에서 크게 개선되었습니다. 세금 500만 달러를 제하고 2분기 순이익은 1,780만 달러 (희석 주당순이익 0.23달러)로, 전년 동기 390만 달러 손실에서 흑자로 전환했습니다; 6개월 순이익은 2,640만 달러였습니다.

유동성은 강화되었습니다: 현금, 현금성 자산 및 미국 국채 투자액이 연말 대비 6,400만 달러 증가한 3억 780만 달러로 늘었으며, 5,040만 달러의 영업 현금 흐름과 Huadong으로부터 받은 2,000만 달러 이정표 수익이 도움이 되었습니다. 총 자산은 6억 6,110만 달러, 자본은 4억 9,500만 달러이며, ARCALYST 공급을 위한 제조 기술 이전 승인에 대비해 재고가 5,300만 달러로 증가했습니다.

전략 업데이트: 1) 2024년 버뮤다에서 영국으로의 재등록 완료; 2) 2025년 4월 Huadong의 mavrilimumab 라이선스 종료로 최대 5억 7,600만 달러의 잠재적 이정표 제거; 3) 남은 상승 잠재력에는 Genentech의 잠재적 이정표 5억 7,000만 달러 (vixarelimab) 및 Huadong의 ARCALYST 판매 이정표 5,000만 달러, 그리고 두 자릿수 중반대 로열티 수익이 포함됩니다.

회사는 현재 유동성이 12개월 이상 운영 자금을 지원할 것으로 기대하고 있습니다.

Kiniksa Pharmaceuticals (KNSA) a réalisé son premier deuxième trimestre bénéficiaire. Le chiffre d'affaires net produit a augmenté de 44 % en glissement annuel pour atteindre 156,8 millions de dollars, grâce à la montée en puissance continue d'ARCALYST, portant les ventes semestrielles à une hausse de 56 % à 294,6 millions de dollars. Le coût des marchandises vendues est resté faible (Q2 COGS à 12 % des ventes), maintenant une marge brute d'environ 88 %.

Les dépenses d'exploitation ont augmenté de 26 % pour atteindre 136,6 millions de dollars, principalement dues aux dépenses de collaboration liées aux accords avec Genentech et Huadong, mais l'effet de levier du chiffre d'affaires plus élevé a fait passer le résultat opérationnel à 20,2 millions de dollars (contre -0,1 million l'année précédente). Après 5,0 millions de taxes, le bénéfice net du T2 a atteint 17,8 millions de dollars (BPA dilué de 0,23 dollar) contre une perte de 3,9 millions un an plus tôt ; le bénéfice net semestriel s'élève à 26,4 millions de dollars.

La liquidité s'est renforcée : la trésorerie, les équivalents de trésorerie et les investissements en bons du Trésor américain ont augmenté à 307,8 millions de dollars (en hausse de 64 millions depuis la fin de l'année), soutenus par un flux de trésorerie opérationnel de 50,4 millions et un paiement d'étape de 20 millions de Huadong. L'actif total s'élève à 661,1 millions avec des capitaux propres de 495,0 millions ; les stocks ont augmenté à 53,0 millions alors que la société prépare l'approbation du transfert technologique de fabrication d'ARCALYST.

Mises à jour stratégiques : 1) La redomiciliation des Bermudes au Royaume-Uni a été complétée en 2024 ; 2) La résiliation en avril 2025 de la licence Huadong pour le mavrilimumab supprime jusqu'à 576 millions de dollars de jalons potentiels ; 3) Le potentiel restant inclut 570 millions de jalons potentiels de Genentech (vixarelimab) et 50 millions de jalons de ventes ARCALYST de Huadong, ainsi que des flux de redevances à deux chiffres moyens.

L'entreprise prévoit que la liquidité actuelle financera les opérations pendant ≥12 mois.

Kiniksa Pharmaceuticals (KNSA) erzielte sein erstes profitables zweites Quartal. Der Nettoumsatz aus Produkten stieg im Jahresvergleich um 44 % auf 156,8 Mio. USD, bedingt durch die anhaltende Nachfrage nach ARCALYST, was den Umsatz in den ersten sechs Monaten um 56 % auf 294,6 Mio. USD erhöhte. Die Herstellungskosten blieben niedrig (Q2 COGS 12 % des Umsatzes), was eine Bruttomarge von etwa 88 % sicherte.

Die Betriebskosten stiegen um 26 % auf 136,6 Mio. USD, getrieben durch Ausgaben im Rahmen von Kooperationen mit Genentech und Huadong, doch durch den höheren Umsatz konnte das Betriebsergebnis auf 20,2 Mio. USD gesteigert werden (vorjahr -0,1 Mio.). Nach Steuern von 5,0 Mio. USD erreichte der Nettogewinn im Q2 17,8 Mio. USD (verwässertes EPS 0,23 USD) gegenüber einem Verlust von 3,9 Mio. USD im Vorjahr; der Nettogewinn für sechs Monate lag bei 26,4 Mio. USD.

Die Liquidität verbesserte sich: Bargeld, Zahlungsmitteläquivalente und US-Staatsanleihen stiegen um 64 Mio. USD seit Jahresende auf 307,8 Mio. USD, unterstützt durch einen operativen Cashflow von 50,4 Mio. und eine Meilensteinzahlung von 20 Mio. USD von Huadong. Die Gesamtaktiva belaufen sich auf 661,1 Mio. USD bei einem Eigenkapital von 495,0 Mio. USD; die Vorräte stiegen auf 53,0 Mio. USD, da das Unternehmen die ARCALYST-Versorgung vor der Genehmigung des Technologietransfers für die Herstellung vorpositioniert.

Strategische Updates: 1) Umzug des Firmensitzes von Bermuda nach Großbritannien im Jahr 2024 abgeschlossen; 2) Die Kündigung der Huadong-Lizenz für mavrilimumab im April 2025 eliminiert bis zu 576 Mio. USD potenzielle Meilensteine; 3) Verbleibende Chancen umfassen 570 Mio. USD potenzielle Meilensteine von Genentech (vixarelimab) und 50 Mio. USD ARCALYST-Verkaufsmeilensteine von Huadong sowie mittlere zweistellige Lizenzgebührenströme.

Das Unternehmen erwartet, dass die aktuelle Liquidität die Betriebsführung für ≥12 Monate sichert.

Positive
  • Revenue up 44% YoY to $156.8 m, demonstrating strong ARCALYST adoption.
  • First quarterly net profit: $17.8 m vs. prior-year loss; diluted EPS $0.23.
  • Operating cash flow $50.4 m for six months, boosting cash to $307.8 m.
  • High gross margin (~88%) maintained despite higher volumes.
  • $570 m potential milestones from Genentech plus ongoing mid-teens royalties remain intact.
Negative
  • Termination of Huadong mavrilimumab license removes up to $576 m future milestones and associated royalties.
  • Revenue concentration risk: ARCALYST accounts for virtually all sales.
  • Collaboration expenses up 75% YoY to $52.4 m, pressuring future margins if growth slows.
  • Inventory jump to $53 m hinges on timely regulatory approval of new manufacturing site.

Insights

TL;DR: Revenue surge, first clean profit, cash up—offset by lost mavrilimumab milestones.

Profitability inflection. ARCALYST demand pushed revenue >$150 m, flipping to positive EPS and validating the commercial model with ~88% gross margin. Opex growth is contained relative to top-line, showing operating leverage.

Cash runway strengthened. $308 m liquidity and positive OCF give at least a year of funding without equity raise—critical in current biotech markets. Deferred tax asset ($206 m) offers future shield.

Pipeline value mix shifts. Huadong’s cancellation removes sizable mavrilimumab economics, modestly trimming long-term optionality. However, $570 m of Genentech milestones plus royalties on three indications keep non-dilutive upside alive.

Risk. ARCALYST concentration—single product supplies nearly 100% of revenue. Inventory build assumes smooth FDA clearance of Samsung Biologics tech-transfer; delays could pressure margins and cash.

TL;DR: Fundamentals improving; headline risks remain product, partner and tax domicile.

Marked transition to profitability reduces financing risk and lowers beta versus cash-burn biotech peers. Terminated mavrilimumab deal is a setback but not cash-impactful near-term. Equity structure remains complex (four ordinary share classes, insiders control Class B), potentially limiting governance influence for new investors. Redomiciliation to U.K. may introduce unfamiliar legal framework for U.S. holders.

Kiniksa Pharmaceuticals (KNSA) ha registrato il suo primo secondo trimestre in utile. I ricavi netti da prodotti sono aumentati del 44% su base annua, raggiungendo 156,8 milioni di dollari, grazie alla continua crescita delle vendite di ARCALYST, che hanno portato le vendite semestrali a un incremento del 56%, a 294,6 milioni di dollari. Il costo del venduto è rimasto basso (Q2 COGS al 12% delle vendite), mantenendo un margine lordo di circa l'88%.

Le spese operative sono cresciute del 26%, arrivando a 136,6 milioni di dollari, principalmente a causa delle collaborazioni con Genentech e Huadong, ma il maggior fatturato ha permesso di ottenere un reddito operativo di 20,2 milioni di dollari (rispetto a -0,1 milioni nel periodo precedente). Dopo 5,0 milioni di dollari di tasse, il reddito netto del secondo trimestre ha raggiunto 17,8 milioni di dollari (EPS diluito 0,23 dollari) contro una perdita di 3,9 milioni dell’anno precedente; il reddito netto semestrale è stato di 26,4 milioni di dollari.

La liquidità si è rafforzata: la somma di liquidità, equivalenti e investimenti in titoli del Tesoro USA è salita a 307,8 milioni di dollari (in aumento di 64 milioni rispetto alla fine dell’anno), favorita da un flusso di cassa operativo di 50,4 milioni e da un pagamento di 20 milioni di dollari da Huadong. Gli attivi totali ammontano a 661,1 milioni di dollari con un patrimonio netto di 495,0 milioni; l’inventario è salito a 53,0 milioni in vista dell’approvazione del trasferimento tecnologico per la produzione di ARCALYST.

Aggiornamenti strategici: 1) nel 2024 è stata completata la redomiciliazione dalle Bermuda al Regno Unito; 2) la cessazione della licenza Huadong per mavrilimumab ad aprile 2025 elimina fino a 576 milioni di dollari in potenziali milestone; 3) le opportunità residue includono 570 milioni di dollari in potenziali milestone da Genentech (vixarelimab) e 50 milioni in milestone di vendita ARCALYST da Huadong, oltre a royalty a due cifre medie.

L’azienda prevede che la liquidità attuale finanzierà le operazioni per almeno 12 mesi.

Kiniksa Pharmaceuticals (KNSA) registró su primer segundo trimestre rentable. Los ingresos netos por productos aumentaron un 44% interanual hasta 156,8 millones de dólares, impulsados por la creciente adopción de ARCALYST, elevando las ventas semestrales un 56% hasta 294,6 millones de dólares. El costo de bienes vendidos se mantuvo bajo (Q2 COGS 12% de las ventas), sosteniendo un margen bruto de aproximadamente el 88%.

Los gastos operativos crecieron un 26% hasta 136,6 millones de dólares, impulsados por gastos de colaboración vinculados a los acuerdos con Genentech y Huadong, pero el apalancamiento del mayor ingreso llevó el ingreso operativo a 20,2 millones de dólares (frente a -0,1 millones el año anterior). Después de 5,0 millones en impuestos, el ingreso neto del Q2 alcanzó 17,8 millones de dólares (EPS diluido de 0,23 dólares) frente a una pérdida de 3,9 millones hace un año; el ingreso neto semestral fue de 26,4 millones de dólares.

La liquidez se fortaleció: el efectivo, equivalentes y las inversiones en bonos del Tesoro de EE.UU. aumentaron a 307,8 millones de dólares (un aumento de 64 millones desde fin de año), apoyados por un flujo de caja operativo de 50,4 millones y un pago de hito de 20 millones de Huadong. Los activos totales son 661,1 millones con un patrimonio neto de 495,0 millones; el inventario aumentó a 53,0 millones mientras la empresa se prepara para la aprobación de transferencia tecnológica de fabricación de ARCALYST.

Actualizaciones estratégicas: 1) Redomiciliación de Bermuda al Reino Unido completada en 2024; 2) La terminación en abril de 2025 de la licencia de mavrilimumab con Huadong elimina hasta 576 millones en posibles hitos; 3) El potencial restante incluye 570 millones en hitos potenciales de Genentech (vixarelimab) y 50 millones en hitos de ventas de ARCALYST de Huadong, además de flujos de regalías de dos dígitos medios.

La compañía espera que la liquidez actual financie las operaciones por ≥12 meses.

Kiniksa Pharmaceuticals (KNSA)가 첫 수익성 있는 2분기를 기록했습니다. 순제품 매출은 ARCALYST의 지속적인 판매 증가로 전년 대비 44% 상승한 1억 5,680만 달러를 기록했으며, 6개월 매출은 56% 증가한 2억 9,460만 달러에 달했습니다. 매출원가는 낮게 유지되어 (2분기 매출원가가 매출의 12%) 약 88%의 총이익률을 유지했습니다.

영업비용은 Genentech 및 Huadong과의 협력 지출로 인해 26% 증가하여 1억 3,660만 달러에 이르렀으나, 매출 증가에 따른 레버리지 효과로 영업이익은 2,020만 달러를 기록하며 전년 동기 -1만 달러에서 크게 개선되었습니다. 세금 500만 달러를 제하고 2분기 순이익은 1,780만 달러 (희석 주당순이익 0.23달러)로, 전년 동기 390만 달러 손실에서 흑자로 전환했습니다; 6개월 순이익은 2,640만 달러였습니다.

유동성은 강화되었습니다: 현금, 현금성 자산 및 미국 국채 투자액이 연말 대비 6,400만 달러 증가한 3억 780만 달러로 늘었으며, 5,040만 달러의 영업 현금 흐름과 Huadong으로부터 받은 2,000만 달러 이정표 수익이 도움이 되었습니다. 총 자산은 6억 6,110만 달러, 자본은 4억 9,500만 달러이며, ARCALYST 공급을 위한 제조 기술 이전 승인에 대비해 재고가 5,300만 달러로 증가했습니다.

전략 업데이트: 1) 2024년 버뮤다에서 영국으로의 재등록 완료; 2) 2025년 4월 Huadong의 mavrilimumab 라이선스 종료로 최대 5억 7,600만 달러의 잠재적 이정표 제거; 3) 남은 상승 잠재력에는 Genentech의 잠재적 이정표 5억 7,000만 달러 (vixarelimab) 및 Huadong의 ARCALYST 판매 이정표 5,000만 달러, 그리고 두 자릿수 중반대 로열티 수익이 포함됩니다.

회사는 현재 유동성이 12개월 이상 운영 자금을 지원할 것으로 기대하고 있습니다.

Kiniksa Pharmaceuticals (KNSA) a réalisé son premier deuxième trimestre bénéficiaire. Le chiffre d'affaires net produit a augmenté de 44 % en glissement annuel pour atteindre 156,8 millions de dollars, grâce à la montée en puissance continue d'ARCALYST, portant les ventes semestrielles à une hausse de 56 % à 294,6 millions de dollars. Le coût des marchandises vendues est resté faible (Q2 COGS à 12 % des ventes), maintenant une marge brute d'environ 88 %.

Les dépenses d'exploitation ont augmenté de 26 % pour atteindre 136,6 millions de dollars, principalement dues aux dépenses de collaboration liées aux accords avec Genentech et Huadong, mais l'effet de levier du chiffre d'affaires plus élevé a fait passer le résultat opérationnel à 20,2 millions de dollars (contre -0,1 million l'année précédente). Après 5,0 millions de taxes, le bénéfice net du T2 a atteint 17,8 millions de dollars (BPA dilué de 0,23 dollar) contre une perte de 3,9 millions un an plus tôt ; le bénéfice net semestriel s'élève à 26,4 millions de dollars.

La liquidité s'est renforcée : la trésorerie, les équivalents de trésorerie et les investissements en bons du Trésor américain ont augmenté à 307,8 millions de dollars (en hausse de 64 millions depuis la fin de l'année), soutenus par un flux de trésorerie opérationnel de 50,4 millions et un paiement d'étape de 20 millions de Huadong. L'actif total s'élève à 661,1 millions avec des capitaux propres de 495,0 millions ; les stocks ont augmenté à 53,0 millions alors que la société prépare l'approbation du transfert technologique de fabrication d'ARCALYST.

Mises à jour stratégiques : 1) La redomiciliation des Bermudes au Royaume-Uni a été complétée en 2024 ; 2) La résiliation en avril 2025 de la licence Huadong pour le mavrilimumab supprime jusqu'à 576 millions de dollars de jalons potentiels ; 3) Le potentiel restant inclut 570 millions de jalons potentiels de Genentech (vixarelimab) et 50 millions de jalons de ventes ARCALYST de Huadong, ainsi que des flux de redevances à deux chiffres moyens.

L'entreprise prévoit que la liquidité actuelle financera les opérations pendant ≥12 mois.

Kiniksa Pharmaceuticals (KNSA) erzielte sein erstes profitables zweites Quartal. Der Nettoumsatz aus Produkten stieg im Jahresvergleich um 44 % auf 156,8 Mio. USD, bedingt durch die anhaltende Nachfrage nach ARCALYST, was den Umsatz in den ersten sechs Monaten um 56 % auf 294,6 Mio. USD erhöhte. Die Herstellungskosten blieben niedrig (Q2 COGS 12 % des Umsatzes), was eine Bruttomarge von etwa 88 % sicherte.

Die Betriebskosten stiegen um 26 % auf 136,6 Mio. USD, getrieben durch Ausgaben im Rahmen von Kooperationen mit Genentech und Huadong, doch durch den höheren Umsatz konnte das Betriebsergebnis auf 20,2 Mio. USD gesteigert werden (vorjahr -0,1 Mio.). Nach Steuern von 5,0 Mio. USD erreichte der Nettogewinn im Q2 17,8 Mio. USD (verwässertes EPS 0,23 USD) gegenüber einem Verlust von 3,9 Mio. USD im Vorjahr; der Nettogewinn für sechs Monate lag bei 26,4 Mio. USD.

Die Liquidität verbesserte sich: Bargeld, Zahlungsmitteläquivalente und US-Staatsanleihen stiegen um 64 Mio. USD seit Jahresende auf 307,8 Mio. USD, unterstützt durch einen operativen Cashflow von 50,4 Mio. und eine Meilensteinzahlung von 20 Mio. USD von Huadong. Die Gesamtaktiva belaufen sich auf 661,1 Mio. USD bei einem Eigenkapital von 495,0 Mio. USD; die Vorräte stiegen auf 53,0 Mio. USD, da das Unternehmen die ARCALYST-Versorgung vor der Genehmigung des Technologietransfers für die Herstellung vorpositioniert.

Strategische Updates: 1) Umzug des Firmensitzes von Bermuda nach Großbritannien im Jahr 2024 abgeschlossen; 2) Die Kündigung der Huadong-Lizenz für mavrilimumab im April 2025 eliminiert bis zu 576 Mio. USD potenzielle Meilensteine; 3) Verbleibende Chancen umfassen 570 Mio. USD potenzielle Meilensteine von Genentech (vixarelimab) und 50 Mio. USD ARCALYST-Verkaufsmeilensteine von Huadong sowie mittlere zweistellige Lizenzgebührenströme.

Das Unternehmen erwartet, dass die aktuelle Liquidität die Betriebsführung für ≥12 Monate sichert.

000130178701/03FALSE2025Q2P1YP1Yhttp://fasb.org/us-gaap/2025#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2025#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2025#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2025#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesbxc:reporting_unitxbrli:purebxc:optionbxc:agreementbxc:segment00013017872024-12-292025-06-2800013017872025-07-2500013017872025-03-302025-06-2800013017872024-03-312024-06-2900013017872023-12-312024-06-2900013017872025-06-2800013017872024-12-280001301787us-gaap:CommonStockMember2024-12-280001301787us-gaap:AdditionalPaidInCapitalMember2024-12-280001301787us-gaap:RetainedEarningsMember2024-12-280001301787us-gaap:RetainedEarningsMember2024-12-292025-03-2900013017872024-12-292025-03-290001301787us-gaap:CommonStockMember2024-12-292025-03-290001301787us-gaap:AdditionalPaidInCapitalMember2024-12-292025-03-290001301787us-gaap:CommonStockMember2025-03-290001301787us-gaap:AdditionalPaidInCapitalMember2025-03-290001301787us-gaap:RetainedEarningsMember2025-03-2900013017872025-03-290001301787us-gaap:RetainedEarningsMember2025-03-302025-06-280001301787us-gaap:CommonStockMember2025-03-302025-06-280001301787us-gaap:AdditionalPaidInCapitalMember2025-03-302025-06-280001301787us-gaap:CommonStockMember2025-06-280001301787us-gaap:AdditionalPaidInCapitalMember2025-06-280001301787us-gaap:RetainedEarningsMember2025-06-280001301787us-gaap:CommonStockMember2024-09-292024-12-280001301787us-gaap:AdditionalPaidInCapitalMember2024-09-292024-12-280001301787us-gaap:CommonStockMember2023-12-300001301787us-gaap:AdditionalPaidInCapitalMember2023-12-300001301787us-gaap:RetainedEarningsMember2023-12-3000013017872023-12-300001301787us-gaap:RetainedEarningsMember2023-12-312024-03-3000013017872023-12-312024-03-300001301787us-gaap:CommonStockMember2023-12-312024-03-300001301787us-gaap:AdditionalPaidInCapitalMember2023-12-312024-03-300001301787us-gaap:CommonStockMember2024-03-300001301787us-gaap:AdditionalPaidInCapitalMember2024-03-300001301787us-gaap:RetainedEarningsMember2024-03-3000013017872024-03-300001301787us-gaap:RetainedEarningsMember2024-03-312024-06-290001301787us-gaap:CommonStockMember2024-03-312024-06-290001301787us-gaap:AdditionalPaidInCapitalMember2024-03-312024-06-290001301787us-gaap:CommonStockMember2024-06-290001301787us-gaap:AdditionalPaidInCapitalMember2024-06-290001301787us-gaap:RetainedEarningsMember2024-06-2900013017872024-06-290001301787bxc:SpecialtyProductsMember2025-03-302025-06-280001301787bxc:SpecialtyProductsMember2024-03-312024-06-290001301787bxc:SpecialtyProductsMember2024-12-292025-06-280001301787bxc:SpecialtyProductsMember2023-12-312024-06-290001301787bxc:StructuralProductsMember2025-03-302025-06-280001301787bxc:StructuralProductsMember2024-03-312024-06-290001301787bxc:StructuralProductsMember2024-12-292025-06-280001301787bxc:StructuralProductsMember2023-12-312024-06-290001301787us-gaap:OperatingSegmentsMemberbxc:ReportableSegmentMember2025-03-302025-06-280001301787us-gaap:OperatingSegmentsMemberbxc:ReportableSegmentMember2024-03-312024-06-290001301787us-gaap:OperatingSegmentsMemberbxc:ReportableSegmentMember2024-12-292025-06-280001301787us-gaap:OperatingSegmentsMemberbxc:ReportableSegmentMember2023-12-312024-06-290001301787bxc:SalesChannelWarehouseMember2025-03-302025-06-280001301787bxc:SalesChannelWarehouseMember2024-03-312024-06-290001301787bxc:SalesChannelWarehouseMember2024-12-292025-06-280001301787bxc:SalesChannelWarehouseMember2023-12-312024-06-290001301787bxc:SalesChannelDirectMember2025-03-302025-06-280001301787bxc:SalesChannelDirectMember2024-03-312024-06-290001301787bxc:SalesChannelDirectMember2024-12-292025-06-280001301787bxc:SalesChannelDirectMember2023-12-312024-06-290001301787bxc:AdjustmentForSalesDiscountsReturnsAndAllowancesGoodsMember2025-03-302025-06-280001301787bxc:AdjustmentForSalesDiscountsReturnsAndAllowancesGoodsMember2024-03-312024-06-290001301787bxc:AdjustmentForSalesDiscountsReturnsAndAllowancesGoodsMember2024-12-292025-06-280001301787bxc:AdjustmentForSalesDiscountsReturnsAndAllowancesGoodsMember2023-12-312024-06-290001301787us-gaap:ShippingAndHandlingMember2025-03-302025-06-280001301787us-gaap:ShippingAndHandlingMember2024-03-312024-06-290001301787us-gaap:ShippingAndHandlingMember2024-12-292025-06-280001301787us-gaap:ShippingAndHandlingMember2023-12-312024-06-290001301787us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2025-06-280001301787us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-12-280001301787bxc:A60SeniorSecuredNotesDue2029Memberus-gaap:SeniorNotesMember2025-03-302025-06-280001301787bxc:A60SeniorSecuredNotesDue2029Memberus-gaap:SeniorNotesMember2024-03-312024-06-290001301787bxc:A60SeniorSecuredNotesDue2029Memberus-gaap:SeniorNotesMember2024-12-292025-06-280001301787bxc:A60SeniorSecuredNotesDue2029Memberus-gaap:SeniorNotesMember2023-12-312024-06-290001301787bxc:A60SeniorSecuredNotesDue2029Memberus-gaap:SeniorNotesMember2025-06-280001301787us-gaap:RestrictedStockUnitsRSUMember2025-03-302025-06-280001301787us-gaap:RestrictedStockUnitsRSUMember2024-12-292025-06-280001301787srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2024-12-292025-06-280001301787srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMember2024-12-292025-06-280001301787srt:MinimumMember2025-06-280001301787srt:MaximumMember2025-06-280001301787bxc:EquipmentAndVehiclesMemberMember2025-06-280001301787bxc:EquipmentAndVehiclesMemberMember2024-12-280001301787us-gaap:RealEstateMember2025-06-280001301787us-gaap:RealEstateMember2024-12-280001301787bxc:UnfavorableRegulatoryActionUnderpaidDutiesMember2024-12-280001301787bxc:UnfavorableRegulatoryActionUnderpaidDutiesMember2025-06-280001301787bxc:UnfavorableRegulatoryActionUnderpaidDutiesMember2023-12-312024-03-300001301787bxc:UnfavorableRegulatoryActionUnderpaidDutiesMember2024-03-312024-06-290001301787bxc:UnfavorableRegulatoryActionUnderpaidDutiesMember2023-12-312024-06-290001301787srt:MinimumMemberbxc:UnfavorableRegulatoryActionLumberOriginsMember2025-06-280001301787srt:MaximumMemberbxc:UnfavorableRegulatoryActionLumberOriginsMember2025-06-280001301787srt:ScenarioForecastMember2024-12-292026-01-030001301787us-gaap:RestrictedStockUnitsRSUMember2024-03-312024-06-290001301787us-gaap:RestrictedStockUnitsRSUMember2023-12-312024-06-290001301787us-gaap:PerformanceSharesMember2024-12-292025-06-280001301787us-gaap:PerformanceSharesMember2023-12-312024-06-2900013017872023-10-310001301787us-gaap:SubsequentEventMember2025-07-280001301787bxc:A60SeniorSecuredNotesDue2029Memberus-gaap:SeniorNotesMember2024-12-280001301787bxc:ReportableSegmentMember2024-03-312024-06-290001301787us-gaap:OperatingSegmentsMemberbxc:SpecialtyProductsMemberbxc:ReportableSegmentMember2025-03-302025-06-280001301787us-gaap:OperatingSegmentsMemberbxc:SpecialtyProductsMemberbxc:ReportableSegmentMember2024-03-312024-06-290001301787us-gaap:OperatingSegmentsMemberbxc:SpecialtyProductsMemberbxc:ReportableSegmentMember2024-12-292025-06-280001301787us-gaap:OperatingSegmentsMemberbxc:SpecialtyProductsMemberbxc:ReportableSegmentMember2023-12-312024-06-290001301787us-gaap:OperatingSegmentsMemberbxc:StructuralProductsMemberbxc:ReportableSegmentMember2025-03-302025-06-280001301787us-gaap:OperatingSegmentsMemberbxc:StructuralProductsMemberbxc:ReportableSegmentMember2024-03-312024-06-290001301787us-gaap:OperatingSegmentsMemberbxc:StructuralProductsMemberbxc:ReportableSegmentMember2024-12-292025-06-280001301787us-gaap:OperatingSegmentsMemberbxc:StructuralProductsMemberbxc:ReportableSegmentMember2023-12-312024-06-290001301787us-gaap:OperatingSegmentsMemberbxc:DeliveryAndLogisticsMemberbxc:ReportableSegmentMember2025-03-302025-06-280001301787us-gaap:OperatingSegmentsMemberbxc:DeliveryAndLogisticsMemberbxc:ReportableSegmentMember2024-03-312024-06-290001301787us-gaap:OperatingSegmentsMemberbxc:DeliveryAndLogisticsMemberbxc:ReportableSegmentMember2024-12-292025-06-280001301787us-gaap:OperatingSegmentsMemberbxc:DeliveryAndLogisticsMemberbxc:ReportableSegmentMember2023-12-312024-06-290001301787us-gaap:OperatingSegmentsMemberbxc:SalesCostsMemberbxc:ReportableSegmentMember2025-03-302025-06-280001301787us-gaap:OperatingSegmentsMemberbxc:SalesCostsMemberbxc:ReportableSegmentMember2024-03-312024-06-290001301787us-gaap:OperatingSegmentsMemberbxc:SalesCostsMemberbxc:ReportableSegmentMember2024-12-292025-06-280001301787us-gaap:OperatingSegmentsMemberbxc:SalesCostsMemberbxc:ReportableSegmentMember2023-12-312024-06-290001301787us-gaap:OperatingSegmentsMemberbxc:OtherMemberbxc:ReportableSegmentMember2025-03-302025-06-280001301787us-gaap:OperatingSegmentsMemberbxc:OtherMemberbxc:ReportableSegmentMember2024-03-312024-06-290001301787us-gaap:OperatingSegmentsMemberbxc:OtherMemberbxc:ReportableSegmentMember2024-12-292025-06-280001301787us-gaap:OperatingSegmentsMemberbxc:OtherMemberbxc:ReportableSegmentMember2023-12-312024-06-290001301787bxc:ReportableSegmentMember2025-03-302025-06-280001301787bxc:ReportableSegmentMember2024-12-292025-06-280001301787bxc:ReportableSegmentMember2023-12-312024-06-290001301787us-gaap:MaterialReconcilingItemsMemberbxc:ReportableSegmentMember2025-03-302025-06-280001301787us-gaap:MaterialReconcilingItemsMemberbxc:ReportableSegmentMember2024-03-312024-06-290001301787us-gaap:MaterialReconcilingItemsMemberbxc:ReportableSegmentMember2024-12-292025-06-280001301787us-gaap:MaterialReconcilingItemsMemberbxc:ReportableSegmentMember2023-12-312024-06-29


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 FORM 10-Q  
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the quarterly period ended June 28, 2025
 OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number: 001-32383
Blue Logo Tagline.jpg
BlueLinx Holdings Inc. 
(Exact name of registrant as specified in its charter) 
 
Delaware77-0627356
(State of Incorporation)(I.R.S. Employer Identification No.)
  
1950 Spectrum Circle, Suite 300
MariettaGA30067
(Address of principal executive offices)(Zip Code)
 
(770) 953-7000
(Registrant’s telephone number, including area code)
 Not applicable
(Former name, former address and former fiscal year, if changed since last report.)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareBXCNew York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No  
Indicate by check mark whether the registrant has submitted electronically (Section 232.405 of this chapter) every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer Accelerated FilerNon-accelerated FilerSmaller Reporting Company
Emerging Growth Company   
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
                                                                                      
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No
As of July 25, 2025, there were 7,892,416 shares of BlueLinx Holdings Inc. common stock, par value $0.01, outstanding.





BLUELINX HOLDINGS INC.
Form 10-Q
For the Quarterly Period Ended June 28, 2025
 
Table of Contents
 PAGE 
PART I. FINANCIAL INFORMATION
 
Item 1. Financial Statements — BlueLinx Holdings Inc. (Unaudited)
  1
Condensed Consolidated Statements of Operations
1
Condensed Consolidated Balance Sheets
2
Condensed Consolidated Statements of Stockholders' Equity
3
Condensed Consolidated Statements of Cash Flows
4
Notes to Condensed Consolidated Financial Statements
5
Note 1 - Basis of Presentation
5
Note 2 - Inventory
6
Note 3 - Goodwill and Intangible Assets, net
7
Note 4 - Revenue Recognition
7
Note 5 - Debt and Finance Lease Obligations
8
Note 6 - Share-Based Compensation
10
Note 7 - Leases
10
Note 8 - Commitments and Contingencies
13
Note 9 - Income Taxes
14
Note 10 - Earnings Per Share and Stockholders' Equity
14
Note 11 - Fair Value
15
Note 12 - Segment Reporting
16
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
17
Item 3. Quantitative and Qualitative Disclosures About Market Risk
28
Item 4. Controls and Procedures
28
PART II. OTHER INFORMATION
 
Item 1. Legal Proceedings
29
Item 1A. Risk Factors
29
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
29
Item 3. Defaults Upon Senior Securities
29
Item 4. Mine Safety Disclosures
29
Item 5. Other Information
30
Item 6. Exhibits
31
Signatures
32

i

Table of Contents
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
BLUELINX HOLDINGS INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
 
Three Fiscal Months EndedSix Fiscal Months Ended
June 28, 2025June 29, 2024June 28, 2025June 29, 2024
Net sales$780,107 $768,363 $1,489,333 $1,494,607 
Cost of products sold660,418 645,919 1,258,515 1,244,482 
Gross profit119,689 122,444 230,818 250,125 
Operating expenses (income): 
Selling, general, and administrative95,265 89,453 189,358 180,703 
Depreciation and amortization9,790 10,120 19,344 19,553 
Amortization of deferred gains on real estate(983)(984)(1,967)(1,968)
Other operating, net582 8 (1,676)322 
Total operating expenses104,654 98,597 205,059 198,610 
Operating income15,035 23,847 25,759 51,515 
Non-operating expenses:  
Interest expense, net8,457 4,80115,037 9,425
Income before provision for income taxes6,578 19,046 10,722 42,090 
Provision for income taxes2,268 4,710 3,607 10,262 
Net income$4,310 $14,336 $7,115 $31,828 
Basic earnings per share$0.54 $1.65 $0.87 $3.68 
Diluted earnings per share$0.54 $1.65 $0.87 $3.66 
 
See accompanying Notes.
 

1


Table of Contents
BLUELINX HOLDINGS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)
(Unaudited)
As of
 June 28, 2025December 28, 2024
ASSETS
Current assets:  
Cash and cash equivalents$386,765 $505,622 
Receivables, less allowances of $5,024 and $4,344, respectively
278,737 225,837 
Inventories, net391,484 355,909 
Other current assets47,635 46,620 
Total current assets1,104,621 1,133,988 
Property and equipment, at cost475,070 443,628 
Accumulated depreciation(193,902)(194,072)
Property and equipment, net281,168 249,556 
Operating lease right-of-use assets50,652 47,221 
Goodwill55,372 55,372 
Intangible assets, net24,974 26,881 
Deferred income tax asset, net52,215 50,578 
Other non-current assets15,033 14,121 
Total assets$1,584,035 $1,577,717 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:  
Accounts payable$177,990 $170,202 
Accrued compensation12,381 16,706 
Finance lease liabilities - current16,926 12,541 
Operating lease liabilities - current8,803 8,478 
Real estate deferred gains - current3,935 3,935 
Other current liabilities22,682 21,862 
Total current liabilities242,717 233,724 
Long-term debt295,723 295,061 
Finance lease liabilities, less current portion300,631 280,002 
Operating lease liabilities, less current portion43,424 40,114 
Real estate deferred gains, less current portion61,329 63,296 
Other non-current liabilities18,899 19,079 
Total liabilities962,723 931,276 
Commitments and Contingencies
STOCKHOLDERS’ EQUITY:  
Preferred Stock, $0.01 par value, 30,000,000 shares authorized, none outstanding
  
Common Stock, $0.01 par value, 20,000,000 shares authorized,
     7,880,465 and 8,294,798 outstanding, respectively
79 83 
Additional paid-in capital91,863 124,103 
Retained earnings529,370 522,255 
Total stockholders’ equity621,312 646,441 
Total liabilities and stockholders’ equity$1,584,035 $1,577,717 

See accompanying Notes.







2

Table of Contents



BLUELINX HOLDINGS INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In thousands)
(Unaudited)

Common StockAdditional
Paid-In Capital
Retained EarningsStockholders’ Equity
Total
 SharesAmount
Balance, December 28, 20248,295 $83 $124,103 $522,255 $646,441 
Net income— — — 2,805 2,805 
Vesting of restricted stock units18 (a)(a)—  
Compensation related to share-based grants— — 2,522 — 2,522 
Repurchase of shares to satisfy employee tax withholdings(7)(a)(507)— (507)
Common stock repurchases and retirements(186)(2)(15,145)— (15,147)
Balance, March 29, 20258,120 81 110,973 525,060 636,114 
Net income— — — 4,310 4,310 
Vesting of restricted stock units62 1 (1)—  
Compensation related to share-based grants— — 2,341 — 2,341 
Repurchase of shares to satisfy employee tax withholdings(18)(a)(1,245)— (1,245)
Common stock repurchases and retirements(283)(3)(20,205)— (20,208)
Balance, June 28, 20257,881 $79 $91,863 $529,370 $621,312 
 
(a) Activity rounds to less than one thousand dollars


Common StockAdditional
Paid-In Capital
Retained EarningsStockholders’ Equity
Total
 SharesAmount
Balance, December 30, 20238,650 $87 $165,060 $469,139 $634,286 
Net income— — — 17,492 17,492 
Vesting of restricted stock units19 (a)(a)—  
Compensation related to share-based grants— — 2,350 — 2,350 
Repurchase of shares to satisfy employee tax withholdings(7)(a)(907)— (907)
Balance, March 30, 20248,662 87 166,503 486,631 653,221 
Net income— — — 14,336 14,336 
Vesting of restricted stock units57 1 (1)—  
Compensation related to share-based grants— — 1,405 — 1,405 
Repurchase of shares to satisfy employee tax withholdings(16)(a)(1,545)— (1,545)
Common stock repurchases and retirements(152)(2)(15,083)— (15,085)
Balance, June 29, 20248,551 $86 $151,279 $500,967 $652,332 


(a) Activity rounds to less than one thousand dollars


See accompanying Notes.
3

Table of Contents
BLUELINX HOLDINGS INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
Six Fiscal Months Ended
 June 28, 2025June 29, 2024
Cash flows from operating activities:
Net income$7,115 $31,828 
Adjustments to reconcile net income to net cash (used in) provided by operations:
Depreciation and amortization19,344 19,553 
Amortization of debt discount and issuance costs662 660 
Insurance recoveries in excess of carrying values of property & equipment(2,443) 
Provision for deferred income taxes(1,637)(421)
Amortization of deferred gains from real estate(1,967)(1,968)
Share-based compensation4,863 3,755 
Changes in operating assets and liabilities:
Accounts receivable(52,900)(45,127)
Inventories(35,575)(13,935)
Accounts payable7,014 20,123 
Other current assets(2,707)(9,612)
Other assets and liabilities(2,435)(188)
Net cash (used in) provided by operating activities(60,666)4,668 
Cash flows from investing activities: 
Disbursements for property and equipment(15,539)(11,901)
Proceeds from asset sales and insurance recoveries2,605 274 
Net cash used in investing activities(12,934)(11,627)
Cash flows from financing activities: 
Common stock repurchases(35,386)(14,529)
Repurchase of shares to satisfy employee tax withholdings(1,770)(2,452)
Principal payments on finance lease liabilities(8,101)(6,411)
Net cash used in financing activities(45,257)(23,392)
Net change in cash and cash equivalents(118,857)(30,351)
Cash and cash equivalents at beginning of period505,622 521,743 
Cash and cash equivalents at end of period$386,765 $491,392 
Supplemental cash flow information:
Interest paid during the period$23,364 $22,266 
Net income tax payments$3,549 $22,093 
Non-cash investing and financing activities:
Property and equipment acquired under finance leases$32,887 $11,150 
Property and equipment investments funded through accounts payable, net$823 $1,562 
Obligation for shares repurchases not yet settled$ $556 

See accompanying Notes.
4

Table of Contents
BLUELINX HOLDINGS INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
June 28, 2025
(Unaudited)
1. Basis of Presentation
BlueLinx Holdings Inc., including consolidated subsidiaries (collectively, the “Company”), is a leading wholesale distributor of residential and commercial building products in the United States. The Company is a two-step distributor and purchases products from manufacturers and distributes those products to dealers and other suppliers in local markets, who then sell those products to end users. The Company carries a broad portfolio of both branded and private-label stock keeping units (“SKUs”) across two principal product categories: specialty products and structural products. Specialty products include items such as engineered wood, siding, moulding and millwork, outdoor living, specialty lumber and panels, and industrial products. Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh. The Company also provides a wide range of value-added services and solutions aimed at relieving distribution and logistics challenges for its customers and suppliers, while enhancing their marketing and inventory management capabilities.
The Company’s unaudited condensed consolidated financial statements and accompanying notes have been prepared using generally accepted accounting principles in the United States (“GAAP”) and the interim reporting guidance of the U.S. Securities and Exchange Commission (“SEC”). The Company is composed of a single reportable segment for financial reporting purposes. The Company’s consolidated balance sheet as of December 28, 2024 contained herein was derived from the audited consolidated balance sheet included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 28, 2024 (the “2024 Form 10-K”), as filed with the SEC on February 18, 2025. In the opinion of the Company’s management, the unaudited condensed consolidated financial statements reflect all adjustments, which are of a normal recurring nature, necessary for a fair presentation of the Company’s results of operations, financial position, and cash flows for the reporting periods presented.
 
The Company has condensed or omitted certain notes and other information from the unaudited condensed consolidated financial statements presented in this report. Therefore, these condensed financial statements and accompanying notes should be read in conjunction with the Company’s 2024 Form 10-K. The results for the three and six fiscal months ended June 28, 2025 are not necessarily indicative of results that may be expected for the full fiscal year ending January 3, 2026, or any other interim period. For the fiscal reporting periods included in the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, the Company did not have any items of other comprehensive income (loss), nor did the Company have any accumulated other comprehensive income (loss).

The Company operates on a 5-4-4 fiscal calendar and its fiscal year ends on the Saturday closest to December 31st of each year and may comprise 53 weeks in certain years. Fiscal 2025 contains 53 weeks and will end on January 3, 2026. Fiscal 2024 contained 52 weeks and ended on December 28, 2024.

During the first quarter of fiscal 2025, the Company settled certain of the initial insurance claims related to property damaged or destroyed at its Erwin, Tennessee owned facility in late third quarter 2024 due to Hurricane Helene. The Company received insurance proceeds that exceeded the carrying values of the damaged or destroyed assets by $2.4 million, and this amount is included in Other Operating, net on the Company’s unaudited condensed consolidated statement of operations for the six fiscal months ended June 28, 2025.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates based on assumptions about current and, for some estimates, future economic and market conditions, which affect reported amounts and related disclosures in the Company’s financial statements. Although current estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from management’s expectations, which could materially affect the Company’s results of operations and financial position.
5

Table of Contents
Significant Accounting Policies

The Company has made no material changes to its significant accounting policies described in the notes to its consolidated financial statement included in its 2024 Form 10-K. The Company did not adopt any new accounting standards during the six fiscal months ended June 28, 2025.

Recent Accounting Pronouncements - Not Yet Adopted

Income Tax Disclosure Improvement. On December 14, 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-09, Improvements to Income Tax Disclosures (“ASU 2023-09”), which establishes new income tax disclosure requirements in addition to modifying and eliminating certain existing requirements. Under the new guidance, entities must consistently categorize and provide greater disaggregation of information in the rate reconciliation. They must also further disaggregate income taxes paid. The ASU’s disclosure requirements apply to all entities subject to Accounting Standards Codification (“ASC”) No. 740, Income Taxes (“ASC 740”). The overall objective of these disclosure requirements is for an entity, particularly an entity operating in multiple jurisdictions, to disclose sufficient information to enable users of financial statements to understand the nature and magnitude of factors contributing to the difference between the effective income tax rate and the statutory income tax rate. ASU 2023-09 will be effective for the Company for the fiscal 2025 annual reporting period. Since this new ASU addresses only disclosures, the Company does not expect the adoption of this ASU to have any material effects on its financial condition, results of operations or cash flows. The Company is currently evaluating any new disclosures that may be required upon adoption of ASU 2023-09.

Costs and Expenses Disclosures. On November 4, 2024, the FASB issued ASU No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), which establishes new disaggregation disclosure requirements for certain costs and expenses in the notes to the consolidated financial statements. Under the new guidance, an entity must provide details of the components of its expense captions from continuing operations presented on the face of the statement of operations as well as a qualitative description of the amounts remaining that are not separately disaggregated quantitatively. Relevant disclosure categories include purchases of inventory, employee compensation, depreciation and intangible asset amortization. An entity must also disclose the total amount of selling expenses, and in annual reports, its definition thereof. The disclosure of these costs and expenses will be required in addition to and irrespective of their inclusion in other disclosures. ASU 2024-03 will be effective for the Company for the fiscal 2027 annual reporting period and for interim periods beginning in fiscal 2028. Since this new ASU addresses only disclosures, the Company does not expect its adoption to have any material effects on its financial condition, results of operations or cash flows. The Company is currently evaluating the new disclosures that will be required upon adoption of ASU 2024-03.
2. Inventory
The Company’s inventories consist almost entirely of finished goods inventory, with a very limited amount of work-in-process inventory. The cost of all inventories is determined by the moving average cost method. The Company includes all material charges directly incurred in bringing inventory to its existing condition and location, including the cost of inbound freight, volume incentives, inventory adjustments, tariffs, duties and other import fees. The Company evaluates the carrying value of its inventory at the end of each fiscal quarter to ensure that inventory, when viewed by category, is carried at the lower-of-cost-or-net-realizable-value (“LCNRV”). This evaluation also considers matters that may impact the net realizable value of inventory such as damaged or obsolete inventory. Any LCNRV decline that is expected to be restored within the current fiscal year, prior to the inventory being sold, is not recognized in an interim fiscal period. As of June 28, 2025 and December 28, 2024, the carrying values of the Company’s inventory reported on its consolidated balance sheets did not reflect any material adjustments for LCNRV matters. In the second quarter of fiscal 2024, the Company recorded a LCNRV provision of $2.4 million as a result of the decrease in the value of certain of the Company’s structural lumber and panels inventory related to the decline in wood-based commodity market prices as of the end of the reporting period.

Substantially all of the amount reported in Cost of products sold on the Company’s consolidated statement of operations is composed of costs incurred to purchase inventory that is subsequently resold to customers, including costs related to import duties and tariffs. Import duties and tariffs are not typically passed through to customers as separately billed charges. Certain import duties are classified by the U.S. Department of Commerce (the “Commerce Department”) as “anti-dumping or countervailing duties,” and these duties may be subject to periodic review and adjustments by the Commerce Department through a process known as a trade remedy administrative review, which can result in both retroactive and prospective adjustments to duty rates. At the time of importation, the Company tenders anti-dumping duty and countervailing duty cash deposits (as use of that term has been defined by the Commerce Department) to the U.S. Customs and Border Protection (“U.S. Customs”) and accounts for duties and tariffs based on the then-current rates in effect, and records any retroactive adjustments
6

Table of Contents
in the period in which U.S. Customs determines final duty rates at the time entries subject to anti-dumping and countervailing duties liquidate (as use of that term has been defined by the Commerce Department), typically through the resolution of a trade remedy administrative review proceeding.

Retroactive refunds received by the Company for adjustments to certain anti-dumping duties related to imported wood moulding and millwork products were $2.4 million and $16.9 million in the six fiscal months ended June 28, 2025 and June 29, 2024, respectively, with all occurring during the first fiscal quarters of both years. Additionally, the Company received interest related to these refunds of $0.5 million and $2.0 million in the six fiscal months ended June 28, 2025 and June 29, 2024, respectively, with all occurring during the first fiscal quarter of both years. The anti-dumping duty cash deposits were originally paid and accounted for by the Company in prior reporting periods at the then-current rates. Impacted inventories have since been sold. These adjustment amounts are reflected in Cost of products sold and Interest expense, net on the Company’s unaudited condensed consolidated statements of operations for the respective reporting periods. See Note 8, Commitments and Contingencies, for disclosure concerning another matter related to import duties.
3. Goodwill and Intangible Assets, net
During the six fiscal months ended June 28, 2025, the only change to the carrying values of the Company’s Goodwill and Intangible assets, net, was the scheduled amortization of intangible assets, all of which have definite lives. Amortization expense for intangible assets was $1.0 million and $1.0 million for the three fiscal months ended June 28, 2025 and June 29, 2024, respectively, and $1.9 million and $2.0 million for the six fiscal months ended June 28, 2025 and June 29, 2024, respectively.
Goodwill is not subject to amortization but must be tested for impairment at least annually, or more frequently if circumstances indicate an impairment may have occurred. The Company consists of one reporting unit, and any impairment assessment requires the Company to determine if the fair value of the reporting unit’s goodwill is less than its carrying amount. The Company tests goodwill for impairment during the fourth quarter of each fiscal year. In addition, the Company will evaluate the carrying value for impairment between annual impairment tests if an event occurs or circumstances change that would indicate the carrying amount may be impaired.
There were no goodwill impairment charges recorded in the three and six fiscal months ended June 28, 2025 or June 29, 2024, and there were no accumulated goodwill impairment balances as of June 28, 2025 or December 28, 2024. Non-cash provisions for the impairment of goodwill and/or other intangible assets could arise in future reporting periods due to sustained and significant changes in circumstances, such as declines in profitability and cash flow due to long-term deterioration in macroeconomic and industry conditions, the loss of key customers, a sustained decrease in the Company’s share price, or other unanticipated events.
4. Revenue Recognition
The following table presents the Company’s revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues.
Three Fiscal Months EndedSix Fiscal Months Ended
Product typeJune 28, 2025June 29, 2024June 28, 2025June 29, 2024
(In thousands)
Specialty products$543,459 $539,466 $1,022,846 $1,043,300 
Structural products236,648 228,897 466,487 451,307 
Total net sales$780,107 $768,363 $1,489,333 $1,494,607 

The following table presents the Company’s revenues disaggregated by sales channel. Warehouse sales are delivered from the Company’s warehouses. Reload sales are similar to warehouse sales but are shipped from non-warehouse locations, most of which are operated by third parties, where the Company stores owned products to enhance operating efficiencies. The reload channel is employed primarily to service strategic customers that are less economical to service from Company warehouses, and to distribute large volumes of imported products from port facilities. Direct sales are shipped from the manufacturer to the customer and therefore the Company does not take physical possession of the inventory and, as a result, typically generate lower margins than the warehouse and reload distribution channels. The direct distribution channel requires the lowest amount of committed capital and fixed costs.
7

Table of Contents
Three Fiscal Months EndedSix Fiscal Months Ended
Sales channelJune 28, 2025June 29, 2024June 28, 2025June 29, 2024
(In thousands)
Warehouse and reload$639,982 $629,193 $1,221,775 $1,220,961 
Direct155,090 155,351 297,582 305,101 
Customer discounts and rebates(14,965)(16,181)(30,024)(31,455)
Total net sales$780,107 $768,363 $1,489,333 $1,494,607 

The Company generally expenses sales commissions when incurred because the amortization period would typically be one year or less. These expenses are recorded within SG&A expense.

The Company has made an accounting policy election to treat outbound shipping and handling activities as an SG&A expense. Shipping and handling expenses include amounts related to the administration of the Company’s logistical infrastructure, handling of material in its warehouses, and amounts pertaining to the delivery of products to customers, such as fuel and maintenance expenses for mobile fleet, wages for drivers, and third-party freight charges. These expenses were $41.3 million and $37.6 million for the three fiscal months ended June 28, 2025 and June 29, 2024, respectively, and $80.8 million and $75.8 million for the six fiscal months ended June 28, 2025 and June 29, 2024, respectively.

Performance obligations in contracts with customers generally consist solely of the delivery of goods.

5. Debt and Finance Lease Obligations

As of June 28, 2025 and December 28, 2024, debt and finance lease obligations consisted of the following:
As of
June 28, 2025December 28, 2024
(In thousands)
Senior Secured Notes (“2029 Notes”) (1)
$300,000 $300,000 
Revolving Credit Facility (2)
  
Unamortized debt issuance costs(2,031)(2,437)
Unamortized bond discount costs(2,246)(2,502)
295,723 295,061 
Finance lease obligations (3)
317,557 292,543 
Less: current portion of finance lease obligations16,926 12,541 
Total debt and finance leases, net of current portions$596,354 $575,063 

(1) As of June 28, 2025 and December 28, 2024, long-term debt was comprised of $300 million of Senior Secured Notes (“2029 Notes”) issued in October 2021 and maturing November 15, 2029. These notes are presented under the Long-term debt caption of the Company’s unaudited condensed consolidated balance sheets in the net amounts of $295.7 million and $295.1 million as of June 28, 2025 and December 28, 2024, respectively. This balance sheet presentation is net of unamortized discount of $2.2 million and $2.5 million, respectively, and unamortized debt issuance costs of $2.0 million and $2.4 million, respectively, as of June 28, 2025 and December 28, 2024. The Senior Secured Notes are presented in this table at their face value.

(2) Available borrowing capacity under the Revolving Credit Facility was $343.5 million and $346.2 million as of June 28, 2025 and December 28, 2024, respectively. The available borrowing capacity reflects undrawn letters of credit.

(3) Refer to Note 7, Leases, for interest rates associated with finance lease obligations. Amounts on this line include $125.1 million and $125.1 million as of June 28, 2025 and December 28, 2024, respectively, for sale-leasebacks of real estate in fiscal 2019 and fiscal 2020 that did not qualify for sale treatment for accounting purposes.


Interest expense, net on the Company’s unaudited condensed consolidated statements of operations consisted of the following components:
8

Table of Contents
Three Fiscal Months EndedSix Fiscal Months Ended
June 28, 2025June 29, 2024June 28, 2025June 29, 2024
(In thousands)
Interest expense$12,640 $11,181 $24,693 $24,290 
Less: Interest income4,183 6,380 9,656 14,865 
Interest expense, net$8,457 $4,801 $15,037 $9,425 

Interest expense for the reporting periods presented in the above table primarily reflects interest expense for the 2029 Notes, interest expense on finance lease obligations, certain ongoing fees for the Revolving Credit Facility that are classified as interest expense, amortization of debt issuance costs for the 2029 Notes and Revolving Credit Facility, and amortization of original-issue bond discount on the 2029 Notes. Total amortization of debt issuance costs and bond discount costs was $0.3 million and $0.3 million for the three fiscal months ended June 28, 2025 and June 29, 2024, respectively, and $0.7 million and $0.7 million for the six fiscal months ended June 28, 2025 and June 29, 2024, respectively. Interest expense for the three fiscal months ended June 28, 2025 and June 29, 2024 also included expense of $0.5 million and a credit of $0.4 million, respectively, and interest expense for the six fiscal months ended June 28, 2025 and June 29, 2024 also included $0.5 million and $1.2 million, respectively, for estimated interest expense related to import duties that the Company believes it may owe (see Note 8, Commitments and Contingencies).

Interest income for the reporting periods presented in the above table primarily reflects interest earned on the Company’s cash and cash equivalents. The refunds received from U.S. Customs for certain anti-dumping import duties (see Note 2, Inventory) resulted in additional interest income of $0.5 million and $2.0 million in the six fiscal months ended June 28, 2025 and June 29, 2024, respectively, all occurring during the first fiscal quarter of both years.

2029 Notes

Interest expense, excluding amortization of debt issuance costs and bond discount, for the 2029 Notes totaled $4.5 million and $4.5 million for the three fiscal months ended June 28, 2025 and June 29, 2024, respectively, and $9.0 million and $9.0 million for the six fiscal months ended June 28, 2025 and June 29, 2024, respectively. The 2029 Notes pay interest at a fixed annual rate of 6.0% through maturity.


Revolving Credit Facility

As of June 28, 2025 and December 28, 2024, the Company had no outstanding borrowings under the Revolving Credit Facility. Available borrowing capacity, reduced for undrawn letters of credit, under the Revolving Credit Facility was $343.5 million and $346.2 million as of June 28, 2025 and December 28, 2024, respectively. Excess availability, which includes availability under the Revolving Credit Facility plus cash and cash equivalents in qualified deposit accounts, was $730.3 million and $851.8 million as of June 28, 2025 and December 28, 2024, respectively. The Revolving Credit Facility is scheduled to terminate on August 2, 2026, and the Company intends to renew it before that date.


Debt Covenants

The Revolving Credit Facility and the 2029 Notes contain various covenants and restrictions, including customary financial covenants. The Company was in compliance with all such covenants as of June 28, 2025 and December 28, 2024. The Company’s right to make draws on the Revolving Credit Facility may be conditioned upon, among other things, compliance with these covenants. These covenants also limit the Company’s ability to, among other things: incur additional debt; grant liens on assets; make investments; repurchase stock; pay dividends and make distributions; sell or acquire assets, including certain real estate assets, outside the ordinary course of business; engage in transactions with affiliates; and make fundamental business changes.

Finance Lease Obligations

The Company’s finance lease liabilities consist of leases related to equipment, vehicles, and real estate, with the majority of those finance leases related to real estate. For more information on the Company’s finance lease obligations, refer to Note 7, Leases.
9

Table of Contents
6. Share-Based Compensation
The Company incurred stock-based compensation expense of $2.3 million and $1.4 million in the three fiscal months ended June 28, 2025 and June 29, 2024, respectively, and $4.9 million and $3.8 million in the six fiscal months ended June 28, 2025 and June 29, 2024, respectively.

During the three and six fiscal months ended June 28, 2025, the Company issued new grants for 247,261 and 293,923 restricted stock units (“RSUs”), respectively, with grant-date intrinsic values of $16.7 million and $21.0 million, respectively. These new RSU grants are scheduled to vest in one year, in three years, or over three years, depending on the terms of each grant, with vesting dependent on service requirements for all awards and market-based conditions for certain awards. Each RSU grant will potentially result in the future issuance of one share of the Company’s common stock if the vesting conditions are satisfied; however, RSUs with market-based vesting conditions could vest at rates between 50% and 200%.

Under the 2021 BlueLinx Holdings, Inc. 2021 Long-Term Incentive Plan as of June 28, 2025, a net of 273,941 shares of the Company’s common stock remain available for future issuances of equity-based compensation awards.
7. Leases
The Company has operating and finance lease agreements for certain of its distribution facilities, office space, land, mobile fleet, and equipment. Many of these lease agreements are non-cancelable and typically have a defined initial lease term, and some provide options to renew at the Company’s election for specified periods of time. The majority of these lease agreements have remaining lease terms of one to 15 years, some of which include one or more options to extend the lease agreement for typically five years. The Company’s lease agreements generally provide for fixed annual rentals. Certain lease agreements include provisions for escalating rent based on, among other things, contractually defined increases and/or changes in the Consumer Price Index (“CPI”). The known changes to lease payments are included in the lease liability at lease commencement. Unknown changes related to CPI are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred. In addition, a subset of vehicle lease cost is considered variable. Some lease agreements require the Company to pay taxes, insurance, and maintenance expenses associated with the leased assets. The lease agreements do not contain any material residual value guarantees or material restrictive covenants.
The Company determines if an arrangement is a lease at inception and assesses lease classification as either operating or finance at lease inception or modification. Operating lease right-of use (“ROU”) assets and liabilities are presented separately on the Company’s consolidated balance sheets. Finance lease ROU assets are included in property and equipment and the finance lease obligations are presented separately in the Company’s consolidated balance sheets. When a lease does not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of future payments. The Company has also made the accounting policy election to not separate lease components from non-lease components related to the mobile fleet asset class.
The Company’s finance lease liabilities consist of leases related to equipment and vehicles, and real estate. A majority of the Company’s finance leases relate to real estate. During fiscal 2017 and fiscal 2018, the Company entered into real estate financing transactions on certain of its warehouse facilities. These transactions were completed pursuant to sale-leaseback arrangements, and upon their completion, the Company entered into long-term leases on the properties having renewal options. The Company accounted for these transactions in accordance with the ASC 840, Leases, which was the lease accounting standard in effect for the Company at the inception of these arrangements. The Company recorded these transactions as finance lease liabilities on its consolidated balance sheet. Gains on these sale-leaseback transactions were deferred and are being recognized in the Company’s earnings in each subsequent reporting period. As of June 28, 2025 and December 28, 2024, the remaining unrecognized deferred gains related to these transactions were $65.3 million and $67.2 million, respectively, and these deferred gains are being recognized in earnings on a straight-line basis. The Company recognized $1.0 million and $1.0 million of the deferred gains in the three fiscal months ended June 28, 2025 and June 29, 2024, respectively, and $2.0 million and $2.0 million in the six fiscal months ended June 28, 2025 and June 29, 2024, respectively.
The following table presents the assets and liabilities related to the Company’s leases as of June 28, 2025 and December 28, 2024:
10

Table of Contents
As of
Lease Assets and LiabilitiesJune 28, 2025December 28, 2024
(In thousands)
AssetsClassification
Operating lease right-of-use assetsOperating lease right-of-use assets$50,652 $47,221 
Finance lease right-of-use assets (1)
Property and equipment, net160,684 134,319 
Total lease right-of-use assets$211,336 $181,540 
Liabilities
Current portion:
Operating lease liabilitiesOperating lease liabilities - current$8,803 $8,478 
Finance lease liabilitiesFinance lease liabilities - current16,926 12,541 
Non-current portion:
Operating lease liabilitiesOperating lease liabilities - noncurrent43,424 40,114 
Finance lease liabilitiesFinance lease liabilities - noncurrent300,631 280,002 
Total lease liabilities$369,784 $341,135 
(1) Finance lease right-of-use assets are presented net of accumulated amortization of $107.9 million and $112.3 million as of June 28, 2025 and December 28, 2024, respectively.

The components of lease expense were as follows:
Three Fiscal Months EndedSix Fiscal Months Ended
Components of lease expenseJune 28, 2025June 29, 2024June 28, 2025June 29, 2024
(In thousands)
Operating lease expense:
Operating lease expense before sublease income$3,100 $2,633 $6,140 $5,079 
Sublease income(928)(887)(1,856)(1,748)
Operating lease expense$2,172 $1,746 $4,284 $3,331 
Finance lease expense:
   Amortization of right-of-use assets$4,802 $5,026 $9,426 $9,762 
   Interest on lease liabilities6,980 6,410 13,853 12,701 
Total finance lease expense$11,782 $11,436 $23,279 $22,463 

Supplemental cash flow information related to leases is as follows:
Three Fiscal Months EndedSix Fiscal Months Ended
June 28, 2025June 29, 2024June 28, 2025June 29, 2024
(In thousands)
Cash paid for amounts included in the measurement of lease liabilities:
   Operating cash flows, operating leases$3,074 $2,693 $6,007 $5,202 
   Operating cash flows, finance leases$6,980 $6,410 $13,853 $12,701 
   Financing cash flows, finance leases$3,832 $3,339 $8,101 $6,411 
11

Table of Contents

Non-cash supplemental cash flow information related to leases is as follows:
Three Fiscal Months EndedSix Fiscal Months Ended
Non-cash informationJune 28, 2025June 29, 2024June 28, 2025June 29, 2024
(In thousands)
Right-of-use assets obtained in exchange for lease obligations:
Operating leases$3,959 $8,132 $3,959 $8,132 
Finance leases$4,801 $2,973 $32,887 $11,150 
Supplemental balance sheet information related to leases is as follows:
As of
Balance Sheet InformationJune 28, 2025December 28, 2024
($ in thousands)
Finance leases
   Property and equipment$268,552$246,635
   Accumulated depreciation(107,868)(112,316)
Property and equipment, net$160,684$134,319
Weighted Average Remaining Lease Term (in years)
   Operating leases7.688.34
   Finance leases16.4117.68
Weighted Average Discount Rate
   Operating leases8.11 %8.15 %
   Finance leases8.74 %8.88 %
The major categories of the Company’s obligations under finance leases as of June 28, 2025 and December 28, 2024 were as follows:
As of
June 28, 2025December 28, 2024
Category:(In thousands)
Equipment and vehicles$75,570 $49,785 
Real estate(1)
241,987 242,758 
Total finance leases$317,557 $292,543 
(1)Amounts include $125.1 million and $125.1 million as of June 28, 2025 and December 28, 2024, respectively, for sale-leasebacks of real estate in fiscal 2019 and fiscal 2020 that did not qualify for sale treatment for accounting purposes.
Below is a summary of undiscounted finance and operating lease liabilities that have initial terms in excess of one year as of June 28, 2025. The table also includes a reconciliation of the future undiscounted cash flows to the present value of the finance and operating lease liabilities included in the unaudited condensed consolidated balance sheet, including options to extend lease terms that are reasonably certain of being exercised.
12

Table of Contents
Fiscal Year:Operating LeasesFinance Leases
(In thousands)
2025 (remainder of fiscal year)$6,555 $21,674 
202610,900 46,945 
202710,031 41,356 
20289,238 41,571 
20297,803 38,313 
Thereafter27,704 484,235 
Total lease payments$72,231 $674,094 
Less: imputed interest(20,004)(356,537)
Total$52,227 $317,557 

8. Commitments and Contingencies
Regulatory Matters
Government and regulatory agencies may have the ability to conduct routine audits and periodic examinations of, and administrative proceedings regarding, the Company’s business operations. As previously disclosed, U.S. Customs gathered initial information from the Company under routine audit procedures, and the information indicated that the Company potentially underpaid duties in prior periods arising from certain classification discrepancies for products imported into the United States as separately entered shipments. In working with U.S. Customs, the Company has exercised reasonable care to address this matter in an equitable and expeditious manner through the filing of a prior disclosure submission with U.S. Customs. As of June 28, 2025 and December 28, 2024, the Company estimated that it will be required to pay approximately $8.0 million, excluding any interest. This amount is reflected in Other current liabilities on the Company’s unaudited condensed consolidated balance sheet as of June 28, 2025 and December 28, 2024. On the Company’s unaudited condensed consolidated statements of operations, a $10.4 million estimate, excluding interest, was accrued for this matter during the first fiscal quarter of 2024. Due to a change in estimate, this amount was reduced by $2.7 million in the second fiscal quarter of 2024, for a net expense of $7.7 million in the six fiscal months ended June 29, 2024. Additional adjustments to the estimated liability were made in fiscal 2024 subsequent to June 29, 2024 to adjust the estimated liability to the $8.0 million as of June 28, 2025 and December 28, 2024. These estimated expense accruals and related adjustments were recorded within Cost of products sold. See Note 2, Inventory, for disclosure concerning another matter related to import duties.
In addition, as previously disclosed, U.S. Customs issued proposed notices of action to the Company, asking for confirmation that certain plywood products the Company imported into the United States originated from Vietnam and Indonesia, respectively, as opposed to China. The Company has provided responses to U.S. Customs and believes that the information it has provided supports the declared origins of the plywood. On July 21, 2025, the Company received a notice from U.S. Customs concluding that the plywood imports under review from Indonesia were found not to originate from China, thereby concluding that matter without any action being taken by U.S. Customs. The Company understands that the review by U.S. Customs of the Company’s imports of certain plywood products from Vietnam remains pending; if the government disagrees with the Company and determines the plywood from Vietnam that was identified in the proposed notice of action originated from China, the Company believes it is reasonably possible that it could be responsible for additional duties on the entries identified by U.S. Customs that could range from zero to $4 million.

Environmental Matters
From time to time, the Company may be involved in proceedings involving various environmental and pollution control laws and regulations in the jurisdictions in which it operates. When the Company believes it has material financial exposure to these matters, it estimates and recognizes adequate liabilities and, if applicable, also timely records any expected recoveries from insurance coverages or subrogation in accordance with GAAP. Such liabilities, when recorded, may or may not be discounted, as required or permitted by GAAP. Based on presently available information, the Company had no material obligations for environmental matters as of June 28, 2025 or December 28, 2024.

Collective Bargaining Agreements
As of June 28, 2025, approximately 19.8% of the Company’s employees were represented by various local labor unions with terms and conditions of employment governed by collective bargaining agreements (“CBAs”). Four CBAs covering
13

Table of Contents
approximately 5.4% of the Company’s employees are up for renewal during the remainder of fiscal 2025, of which two are set to be voted on by August 2025, one is currently being negotiated, and one is expected to be renegotiated before its renewal date.

9. Income Taxes

Effective Income Tax Rate

The Company’s effective income tax rates for the three fiscal months ended June 28, 2025 and June 29, 2024 were 34.5% and 24.7%, respectively. For the six fiscal months ended June 28, 2025 and June 29, 2024, the Company’s effective income tax rates were 33.6% and 24.4%, respectively.

The Company’s effective income tax rates for the three and six fiscal months ended June 28, 2025 were both impacted by the permanent addback of certain nondeductible expenses, including meals and entertainment and executive compensation for the quarterly periods, as well as adjustments to deferred income tax assets related to stock-based compensation which increased the effective income tax rate.

The Company’s effective income tax rates for the three and six fiscal months ended June 29, 2024 were both impacted by the permanent addback of certain nondeductible expenses, including meals and entertainment and executive compensation, partially offset by a benefit from the vesting of restricted stock units in the fiscal periods. The income tax rate for the six fiscal months ended June 29, 2024 benefited from a partial release of a state income tax valuation allowance for deferred income tax assets, which impacted only the first quarter of 2024.

For fiscal 2025, the Company currently estimates that its annual effective income tax rate will be approximately 27%. On July 4, 2025, the law formally titled “An Act to Provide for the Reconciliation Pursuant to Title II of H. Con. Res. 14” (commonly referred to as the “One Big Beautiful Bill” or “OBBB”) was signed into law. The Company is evaluating the potential impacts that the OBBB may have on the Company’s income tax expense and deferred income tax assets and liabilities, including new provisions for bonus depreciation on certain types of assets. However, at this time, the Company does not believe the OBBB will have a material impact on its annual effective income tax rate for fiscal 2025.

For additional information about the Company’s income taxes, see Note 7, Income Taxes, to the consolidated financial statements included in Item 8 of the Company’s Annual Report on Form 10-K for the fiscal year ended December 28, 2024.

10. Earnings Per Share and Stockholders' Equity
The Company calculates basic earnings per share by dividing net income for the period by the weighted average number of common shares outstanding for the period. For rounding purposes when calculating earnings per share, the Company’s policy is to round down to the whole cent.

Diluted earnings per share are calculated using the treasury stock method whereby net income for the period is divided by the weighted average number of common shares outstanding for the period plus the dilutive effect, if any, of shares of stock associated with unvested share-based grants. However, for performance-based share-based grants, the dilutive effect is included only for grants where the performance goals have been achieved.

The reconciliations of basic net income and diluted earnings per common share for the three and six fiscal months ended June 28, 2025 and June 29, 2024 are as follows:
Three Fiscal Months EndedSix Fiscal Months Ended
June 28, 2025June 29, 2024June 28, 2025June 29, 2024
Net income (in thousands)$4,310 $14,336 $7,115 $31,828 
Weighted-average shares outstanding - Basic7,935,268 8,644,839 8,095,741 8,640,976 
Dilutive effect of share-based awards41,754 40,789 60,985 38,550 
Weighted-average shares outstanding - Diluted7,977,022 8,685,628 8,156,726 8,679,526 
Basic earnings per share$0.54 $1.65 $0.87 $3.68 
Diluted earnings per share$0.54 $1.65 $0.87 $3.66 
14

Table of Contents
Weighted-average unvested restricted stock units (“RSUs”) totaling 122,983 and 43,471 for the three and six month fiscal periods ended June 28, 2025, respectively, and 23,627 and 2,488 for the three and six month fiscal periods ended June 29, 2024, respectively, were not included in the dilutive effect of share-based awards for the respective periods because their effects were antidilutive. Additionally, as of June 28, 2025 and June 29, 2024, a total of 119,630 and 145,219, respectively, of certain unvested performance-based RSUs were outstanding but not included in the computation of diluted earnings per share because their performance metrics had not been achieved and thus they were not tested for dilution under the treasury stock method. Any outstanding RSU’s dilutive effect could change in future reporting periods.
Repurchases of Common Stock
On October 31, 2023, the Company’s board of directors authorized a share repurchase program for $100 million. During the three and six fiscal months ended June 28, 2025, the Company repurchased 283,081 and 469,129 shares, respectively, of its common stock at a weighted-average average price of $70.68 and $74.64, respectively, including broker commissions but excluding federal excise tax on the repurchases, for a total of $20.0 million and $35.0 million, respectively. These amounts are based on trade date activity, while the amounts reported on the Company’s consolidated statements of cash flows for share repurchases are based on settlement date activity. As of June 28, 2025, there remained approximately $11.5 million repurchase capacity under the authorization approved October 31, 2023.
Between June 28, 2025 and July 25, 2025, the Company did not repurchase any additional shares of its common stock.
On July 28, 2025, the Company’s board of directors authorized a new share repurchase program for $50 million. The 2025 authorization may be used after exhaustion of the 2023 authorization.

Under its share repurchase programs, the Company may repurchase its common stock from time to time, without prior notice, subject to prevailing market conditions and other considerations. Repurchases may be made through a variety of methods, which may include open market purchases, privately negotiated transactions, accelerated share repurchase programs, tender offers or pursuant to a trading plan that may be adopted in accordance with the Securities and Exchange Commission Rule 10b5-1.

11. Fair Value

As of June 28, 2025 and December 28, 2024, the Company had no assets or liabilities for which the carrying value is remeasured to fair value at the end of each reporting period. The Company has not elected the fair value reporting option for any of its financial instruments.

Fair Value Disclosures

The fair value of cash, cash equivalents, accounts receivable, accounts payable and accrued liabilities, to the extent the underlying liability will be settled in cash, approximates the carrying values because of the short-term nature of these instruments.

Debt

The estimated fair value of the Company’s $300 million 2029 Notes was determined based on Level 2 input using observable market prices in less active markets, as presented below:
As of
June 28, 2025December 28, 2024
Carrying Value(1)
Fair Value
Carrying Value(1)
Fair Value
 (In thousands)
2029 Notes$295,723 $288,000 $295,061 $293,597 
(1) The $300 million obligation for the 2029 Notes is presented on the Company’s consolidated balance sheets net of unamortized debt issuance costs and discount totaling $4.3 million and $4.9 million as of June 28, 2025 and December 28, 2024, respectively. Periodic amortization of the issuance costs and discount each reporting period causes the carrying value of the 2029 Notes to gradually increase to the $300 million maturity amount scheduled for November 15, 2029. See Note 5, Debt and Finance Lease Obligations.
There were no borrowings outstanding under the Company’s Revolving Credit Facility during the three and six fiscal months ended June 28, 2025 or during fiscal year 2024.
15

Table of Contents

12. Segment Reporting

The Company has one reportable segment: building products. The segment sells building products that are grouped into two primary categories: specialty products and structural products. The Company’s chief operating decision maker (“CODM”), as that term is defined under U.S. GAAP, is its chief executive officer (CEO). The Company derives substantially all of its revenues from the United States and all of the Company’s assets are located in the United States. The measure of segment assets is reported on the Company’s balance sheet as total consolidated assets. The segment’s accounting policies are the same as the accounting policies for the Company, as described in Note 1, Summary of Significant Accounting Policies, in Part II, Item 8 of the Company’s most recent Annual Report on Form 10-K.

The CODM’s method under GAAP that is used to assess performance and allocate resources is based on Net income as reported on the Company’s consolidated statement of operations. The following table presents information about Net income and significant expenses that are regularly reviewed by the Company’s CODM:

Three Fiscal Months EndedSix Fiscal Months Ended
June 28, 2025June 29, 2024June 28, 2025June 29, 2024
(In thousands)
Net sales$780,107 $768,363 $1,489,333 $1,494,607 
Expenses:
Cost of specialty products sold443,177 435,116 832,786 834,901 
Cost of structural products sold217,241 210,803 425,729 409,581 
SG&A - delivery and logistics41,343 37,608 80,781 75,764 
SG&A - sales18,519 17,420 36,276 34,848 
SG&A - all other35,403 34,425 72,301 70,091 
Depreciation of property and equipment8,836 9,140 17,437 17,548 
Amortization of definite-lived intangible assets954 980 1,907 2,005 
Amortization of deferred gains on real estate(983)(984)(1,967)(1,968)
Interest expense12,640 11,181 24,693 24,290 
Interest income(4,183)(6,380)(9,656)(14,865)
Other operating, net582 8 (1,676)322 
Provision for income taxes2,268 4,710 3,607 10,262 
Total segment expenses775,797 754,027 1,482,218 1,462,779 
Segment net income4,310 14,336 7,115 31,828 
Reconciliation of profit or loss:
Adjustments and reconciling items    
Consolidated net income$4,310 $14,336 $7,115 $31,828 

During the first quarter of fiscal 2025, the Company settled certain of the initial insurance claims related to property and equipment that was damaged or destroyed at its Erwin, Tennessee owned facility in late third quarter of fiscal 2024 due to Hurricane Helene. The Company received insurance proceeds that exceeded the carrying values of the damaged or destroyed assets by $2.4 million and this amount is included in Other Operating, net on the Company’s unaudited condensed consolidated statement of operations for the six fiscal months ended June 28, 2025.
16

Table of Contents
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Cautionary Statement Concerning Forward-Looking Statements

This Quarterly Report on Form 10-Q (“Quarterly Report” or “Form 10-Q”) contains forward-looking statements. Forward-looking statements include, without limitation, any statements that predict, forecast, indicate or imply future results, performance, liquidity levels or achievements, and may contain the words “believe,” “anticipate,” “could,” “expect,” “estimate,” “intend,” “may,” “project,” “plan,” “should,” “will,” “will be,” “will likely continue,” “will likely result,” “would,” or words or phrases of similar meaning. Forward-looking statements are based on estimates and assumptions made by our management that, although believed by us to be reasonable, are inherently uncertain. Forward-looking statements involve risks and uncertainties that may cause our business, strategy, or actual results to differ materially from the forward-looking statements. The forward-looking statements in this report include, without limitation, statements about anticipated effects of adopting certain accounting standards; estimated future annual amortization expense; estimates made in connection with revenue recognition; the expected outcome of legal proceedings; the expected outcome of government and regulatory proceedings; industry conditions; seasonality; liquidity and capital resources; our confidence in the Company’s long-term growth strategy; our areas of focus and management initiatives; the demand outlook for construction materials and expectations regarding new home construction, repair and remodel activity and continued investment in existing and new homes; our positioning for long-term value creation; our efforts and ability to generate profitable growth; our ability to increase net sales in specialty product categories; our ability to generate profits and cash from sales of specialty products; our ability to effectively manage inventory; our ability to manage our lease commitments; our ability to negotiate collective bargaining agreements; our multi-year capital allocation plans; our ability to manage volatility in wood-based commodities; our improvement in execution and productivity; our efforts and ability to maintain a disciplined capital structure and capital allocation strategy; our ability to maintain a strong balance sheet; our ability to focus on operating improvement initiatives and commercial excellence; and whether or not the Company will continue any share repurchases.

These risks and uncertainties also include those discussed under the heading “Risk Factors” in Part II, Item 1A of this Form 10-Q, under the heading “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 28, 2024, as supplemented in Part II, Item 1A, “Risk Factors,” in the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 29, 2025, and those risks and uncertainties those discussed elsewhere in this Form 10-Q, and in future reports that we file with the SEC.

We operate in a changing environment in which new risks can emerge from time to time. It is not possible for management to predict all of these risks, nor can it assess the extent to which any factor, or a combination of factors, may cause our business, strategy, or actual results to differ materially from those contained in forward-looking statements. Given these risks and uncertainties, we caution you not to place undue reliance on forward-looking statements. We expressly disclaim any obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise, except as required by law.

The following discussion should be read in conjunction with our consolidated financial statements and related notes and other financial information included in this Form 10-Q and in our Annual Report on Form 10-K for fiscal year 2024.

In addition to historical information, the following discussion and other parts of this Form 10-Q contain forward-looking information that involves risks and uncertainties. Our actual results could differ materially from those anticipated by this forward-looking information due to the factors discussed under Part II, Item 1A “Risk Factors” in this Form 10-Q, under Part I, Item 1A “Risk Factors” in our Form 10-K for fiscal 2024, and under “Cautionary Statement Concerning Forward-Looking Statements” in Item 2 of this Form 10-Q.

Our Strategy

We remain committed to driving a culture of profitable growth within new and existing product lines and geographies, while positioning the Company for long-term value creation. The following initiatives represent key areas of our management team’s focus:

1.Grow our higher-margin specialty product categories. We continue to pursue a revenue mix weighted toward higher-margin, specialty product categories such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. Additionally, we are expanding our value-added service offerings designed to simplify complex customer sourcing requirements.
17

Table of Contents
2.Increase share gain in local and national markets. We continue to pursue multi-family project growth, expand our product lines with key national accounts, expand branded product lines into new geographic markets, and launch new product lines. With our expanded product categories, and our strategic vendor relationships, we seek to be an extension of our customers’ business in a scalable way.

3.Foster a performance-driven culture committed to business excellence and profitable growth to be the provider of choice for both suppliers and customers. We seek to improve the customer experience through enhanced tools, value-added services, and technology enablement, accelerating organic growth within specific product and solutions offerings where we are uniquely advantaged, increase our performance by leveraging our scale and national footprint together with pricing, operational and procurement capabilities, and deploy capital to drive sustained margin expansion, grow cash flow and maintain continued profitable growth.

4.Maintain a disciplined capital structure and pursue strategic investments that increase the value of the Company. We continue to strategically target acquisition opportunities that grow our higher-margin specialty products business, expand our geographic reach, or complement our existing capabilities. We also continue to evaluate and identify additional markets that are potential opportunities for new market development. We further seek to maintain a disciplined capital structure while at the same time investing in our business to modernize our distribution facilities, as well as our tractor and trailer fleet, and to improve operational performance. During the six fiscal months ended June 28, 2025, we engaged in the following transactions:

Used cash of $15.5 million and entered into $32.9 million of finance leases to enhance our facilities and fleet.
Returned capital of $35 million to our shareholders by using cash to purchase 469,129 shares of our common stock at an average price of $74.61, excluding broker commissions and excise tax.

Our culture is guided by our values:
Customer Centric - We put our customers first, so we are customer centric in all that we do.
Integrity - We act with integrity, because doing the right thing is critical to our success.
Respect - We treat everyone with dignity and respect.
Grit - We show grit in the face of changing landscapes.
Collaboration - We collaborate with each other and our customers to build great teams and construct innovative solutions.

Factors That Affect Our Operating Results and Trends

Our results of operations and financial performance are influenced by a variety of factors, including the following: adverse housing market conditions; consolidation among competitors, suppliers, and customers; escalating changes in retaliatory trade policies of the United States and other countries; our dependence on international suppliers and manufacturers for certain products and related exposure to risks of new or increased tariffs and other risks that could affect our financial condition; pricing and product cost variability; disintermediation risk; volumes of product sold; competition; the cyclical nature of the industry in which we operate; loss of products or key suppliers and manufacturers; information technology security risks and business interruption risks; effective inventory management relative to our sales volume or the prices of the products we produce; the ability to attract, train, and retain highly qualified associates and other key personnel while controlling related labor costs; potential acquisitions and the integration and completion of such acquisitions; business disruptions; exposure to product liability and other claims and legal proceedings related to our business and the products we distribute; natural disasters, catastrophes, fire, wars or other unexpected events; the impacts of climate change; successful implementation of our strategy; wage increases or work stoppages by our union employees; costs imposed by federal, state, local, and other regulations; compliance costs associated with federal, state, and local environmental protection laws; the effects of epidemics, global pandemics or other widespread public health crises and governmental rules and regulations; fluctuations in our operating results; our level of indebtedness and our ability to incur additional debt to fund future needs; the covenants of the instruments governing our indebtedness limiting the discretion of our management in operating the business; the potential to incur more debt; the fact that we have consummated certain sale leaseback transactions with resulting long-term non-cancelable leases, many of which are or will be finance leases; the fact that we lease many of our distribution centers, and we would still be obligated under these leases even if we close a leased distribution center; inability to raise funds necessary to finance a required repurchase of our senior secured notes; a lowering or withdrawal of debt ratings; changes in our product mix; increases in fuel and other energy prices or availability of third-part freight providers; changes in insurance-related deductible/retention liabilities based on actual loss development experience; the possibility that the value of our deferred tax assets could become impaired; changes in our expected annual effective tax rate could be volatile; the costs and liabilities related to our participation in multi-employer pension plans could increase; the risk that our cash flows and capital resources may be insufficient to service our existing or future indebtedness; interest rate risk, which could cause our debt service obligations to increase; and changes
18

Table of Contents
in, or interpretation of, accounting principles. These factors, and the related trends and uncertainties, have historically produced cyclicality in our results of operations, and we expect this cyclicality to continue in future periods.

For more information on the risk factors impacting our business, refer to Part II, Item 1A, Risk Factors, in this Form 10-Q and to Part I, Item 1A, Risk Factors, in our Annual Report on Form 10-K for the fiscal year 2024, as supplemented in Part II, Item 1A, “Risk Factors,” in the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 29, 2025.
19

Table of Contents
Results of Operations
Our results of operations for the three fiscal months ended June 28, 2025 (“second quarter of fiscal 2025”) and for the three fiscal months ended June 29, 2024 (“second quarter of fiscal 2024”) were as follows:
Three Fiscal Months Ended June 28, 2025% of
Net
Sales
Three Fiscal Months Ended June 29, 2024% of
Net
Sales
($ amounts in thousands)
Net sales$780,107 $768,363 
Gross profit119,689 15.3%122,444 15.9%
Less:
Selling, general, and administrative95,265 12.2%89,453 11.6%
Depreciation and amortization9,790 1.3%10,120 1.3%
Amortization of deferred gains on real estate(983)(0.1)%(984)(0.1)%
Other operating, net582 0.1%—%
Operating income15,035 1.9%23,847 3.1%
Interest expense, net8,457 1.1%4,801 0.6%
Income before provision for income taxes6,578 0.8%19,046 2.5%
Provision for income taxes2,268 0.3%4,710 0.6%
Net income$4,310 0.6%$14,336 1.9%
20

Table of Contents

Our results of operations for the six fiscal months ended June 28, 2025 (“first six months of fiscal 2025”) and for the six fiscal months ended June 29, 2024 (“first six months of fiscal 2024”) were as follows:

Six Fiscal Months Ended June 28, 2025% of
Net
Sales
Six Fiscal Months Ended June 29, 2024% of
Net
Sales
($ amounts in thousands)
Net sales$1,489,333 $1,494,607 
Gross profit230,818 15.5%250,125 16.7%
Selling, general, and administrative189,358 12.7%180,703 12.1%
Depreciation and amortization19,344 1.3%19,553 1.3%
Amortization of deferred gains on real estate(1,967)(0.1)%(1,968)(0.1)%
Other operating, net(1,676)(0.1)%322 —%
Operating income25,759 1.7%51,515 3.4%
Interest expense, net15,037 1.0%9,425 0.6%
Income before provision for income taxes10,722 0.7%42,090 2.8%
Provision for income taxes3,607 0.2%10,262 0.7%
Net income$7,115 0.5%$31,828 2.1%

The following table sets forth net sales by product category and percentage of total net sales by product category:
Three Fiscal Months EndedSix Fiscal Months Ended
June 28, 2025June 29, 2024June 28, 2025June 29, 2024
Net sales by product category:($ amounts in thousands)
Specialty products$543,459 70 %$539,466 70 %$1,022,846 69 %$1,043,300 70 %
Structural products236,648 30 %228,897 30 %466,48731 %451,30730 %
Total net sales$780,107 100 %$768,363 100 %$1,489,333 100 %$1,494,607 100 %


The following table sets forth gross profit, the percentage of total gross profit earned by product category, and gross margin percentages by product category:
Three Fiscal Months EndedSix Fiscal Months Ended
June 28, 2025June 29, 2024June 28, 2025June 29, 2024
Gross profit by product category:($ amounts in thousands)
Specialty products$100,282 84 %$104,350 85 %$190,060 82 %$208,399 83 %
Structural products19,407 16 %18,094 15 %40,758 18 %41,726 17 %
Total gross profit$119,689 100 %$122,444 100 %$230,818 100 %$250,125 100 %
Gross margin % by product category:  
Specialty products18.5%19.3%18.6%20.0%
Structural products8.2%7.9%8.7%9.2%
Company gross margin %15.3%15.9%15.5%16.7%







21

Table of Contents
Second Quarter of Fiscal 2025 Compared to Second Quarter of Fiscal 2024

For the second quarter of fiscal 2025, the Company’s net sales were $780.1 million, an increase of $11.7 million, or 1.5%, compared to the second quarter of fiscal 2024.
The increase in the Company’s net sales in the current fiscal quarter was attributable to both specialty products and structural products. Higher overall volume was partially offset by overall lower pricing driven by external market factors.
Approximately 70% of the Company’s net sales in the second quarter of fiscal 2025 and the second quarter of fiscal 2024 were generated by specialty products.

The Company’s gross profit for the second quarter of fiscal 2025 decreased by $2.8 million, or 2.3%, to $119.7 million from $122.4 million in the prior year quarter.
This overall decrease in the Company’s gross profit in the current fiscal quarter was attributable to specialty products, partially offset by higher gross profit for structural products.
84% of the Company’s gross profit was generated by specialty products in the second quarter of fiscal 2025, compared to 85% in the second quarter of fiscal 2024.
Gross margin percentage for the Company decreased from 15.9% to 15.3% in the current fiscal quarter. This overall decrease in the Company’s gross margin percentage was attributable to specialty products, partially offset by higher gross margin percentage for structural products.
The Company benefited in the second quarter of fiscal 2024 by a $2.7 million change in an estimate for an accrual initially made and disclosed in the first quarter of fiscal 2024 related to amounts we believe we may owe for discrepancies in duties paid in prior years for certain imported goods (see Note 8, Commitments and Contingencies, to the accompanying unaudited condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q). This amount is reported within Cost of products sold on our unaudited condensed consolidated statement of operations for the second quarter of fiscal 2024. As subsequently discussed, this item benefited the operating results for specialty products in the second quarter of fiscal 2024.
The Company was negatively impacted in the second quarter of fiscal 2024 by a $2.4 million interim LCNRV provision to adjust the carrying values of certain structural lumber and structural panel inventory items to their net realizable value as of June 29, 2024. This amount is reported within Cost of products sold on our unaudited condensed consolidated statement of operations for the second quarter of fiscal 2024. As subsequently discussed, this item negatively impacted the operating results for structural products in the second quarter of fiscal 2024. Such adjustments were not material for the second quarter of fiscal 2025.

Specialty products - Net sales of specialty products, which include product types such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products, increased by $4.0 million, or 0.7%, to $543.5 million in the second quarter of fiscal 2025.
This overall increase in net sales for specialty products in the current fiscal quarter was due to higher volume for engineered wood, millwork, and specialty lumber and panels, partially offset by lower pricing mainly on those same product types.
Specialty products gross profit decreased by $4.1 million, or 3.9%, to $100.3 million in the current fiscal quarter due primarily to a competitive pricing environment.
Specialty products gross margin percentage decreased by 80 basis points to 18.5% compared to 19.3% in the second quarter of fiscal 2024 due primarily to a competitive pricing environment.
The $2.7 million adjustment related to duty and import matters discussed above at the Company level benefited the operating results for specialty products in the second quarter of fiscal 2024. Excluding this benefit, specialty products gross margin percentage for second quarter of fiscal 2024 would have been 18.9% compared to 18.5% for the second quarter of fiscal 2025, a decrease of 40 basis points for the current quarter.

Structural products - Net sales of structural products, which include product types such as lumber, panels (including plywood and oriented strand board), rebar, and remesh, increased by $7.8 million, or 3.4%, to $236.6 million in the second quarter of fiscal 2025 compared to $228.9 million in the second quarter of fiscal 2024.
This overall increase in net sales for structural products in the current fiscal quarter was due to higher volume on panels and lumber and higher pricing on lumber, partially offset by lower pricing on panels that was driven by external market factors.
Compared to the second quarter of 2024, average commodity prices in U.S. markets during the second quarter of 2025 for lumber were up 17.6% and down 18.7% for panels. Higher lumber prices were driven by tightening U.S. sawmill output and dwindling import volumes.
Structural products gross profit increased overall by $1.3 million, or 7.3%, to $19.4 million from $18.1 million in the prior year fiscal quarter. Higher net sales in the current quarter were partially offset by margin compression due to
22

Table of Contents
external market factors.
Structural products gross margin percentage for the second quarter of fiscal 2025 was 8.2% compared to 7.9% in the second quarter of fiscal 2024. The interim $2.4 million LCNRV provision discussed above at the Company level negatively impacted the operating results for structural products for the second quarter of fiscal 2024. Such amounts were not material for the second quarter of fiscal 2025.

Our selling, general, and administrative (“SG&A”) expenses increased by $5.8 million, or 6.5%, compared to the second quarter of fiscal 2024. This overall increase was due primarily to increased sales and logistics expenses driven by higher sales volumes, our strategy to grow sales in the multi-family channel, as well as expenses associated with our digital transformation.

Depreciation and amortization expense decreased $0.3 million compared to the second quarter of fiscal 2024. We continue to focus on strategic capital investment.

Interest expense, net, which includes gross interest expense less interest income, was $8.5 million and $4.8 million in the second quarter of fiscal 2025 and second quarter of fiscal 2024, respectively, resulting in an increase in net interest expense of $3.7 million in the current fiscal quarter.
Gross interest expense was $12.6 million and $11.2 million in the second quarter of fiscal 2025 and second quarter of fiscal 2024, respectively. Gross interest expense in the second quarter of fiscal 2025 included additional expense of $0.5 million while interest expense for the second quarter of fiscal 2024 included a benefit of $0.4 million, both related to the aforementioned estimate for an accrual initially made and disclosed in the first quarter of 2024 related to amounts the Company believes it may owe for discrepancies in duties paid in prior years for certain imported goods (see Note 8, Commitments and Contingencies, to the unaudited condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q). Excluding these amounts, gross interest expense in the second quarter of fiscal 2025 and second quarter of fiscal 2024 would have been $12.2 million and $11.6 million, respectively, an increase in the current fiscal quarter of $0.6 million compared to the second quarter of fiscal 2024. This $0.6 million of additional interest expense in the current fiscal quarter was due to additional net finance leases added subsequent to the second quarter of fiscal 2024.
Interest income was $4.2 million and $6.4 million in the second quarter of fiscal 2025 and second quarter of fiscal 2024, respectively. This decrease in the current fiscal quarter was due to lower average balances for interest-bearing deposits of cash/cash equivalents and due to lower interest rates paid on those deposits in the current fiscal quarter.

For fiscal 2025, we currently estimate our annual effective income tax rate will be approximately 27%. Our effective income tax rates were 34.5% and 24.7% for the second quarters of fiscal 2025 and fiscal 2024, respectively. Our effective income tax rates for the second quarters of fiscal 2025 and 2024 were both impacted by the permanent addback of certain nondeductible expenses, including meals and entertainment and executive compensation for the quarterly periods. The effective income tax rate for the second quarter of 2025 was also increased by adjustments to deferred income tax assets related to stock-based compensation. Our effective income tax rate for the second quarter of fiscal 2024 was slightly offset by a benefit from the vesting of restricted stock units. On July 4, 2025, the law formally titled “An Act to Provide for the Reconciliation Pursuant to Title II of H. Con. Res. 14” (commonly referred to as the “One Big Beautiful Bill” or “OBBB”) was signed into law. We are evaluating the potential impacts that the OBBB may have on our income tax expense and deferred income tax assets and liabilities, including new provisions for bonus depreciation on certain types of assets. However, at this time, we do not believe the OBBB will have a material impact on our annual effective income tax rate for fiscal 2025.

Our net income for the second quarter of fiscal 2025 was $4.3 million, or $0.54 per diluted share, versus $14.3 million, or $1.65 per diluted share, in the prior-year fiscal quarter. Decreases in our net income and earnings per diluted share were due primarily to the factors discussed above.

First Six Months of Fiscal 2025 Compared to First Six Months of Fiscal 2024

For the first six months of fiscal 2025, the Company’s net sales were $1.49 billion, a decrease of $5 million, or 0.4%, compared to the first six months of fiscal 2024.
The overall decrease in net sales in the current fiscal period was attributable to specialty products, partially offset by an increase for structural products. Higher overall volume was offset by overall lower pricing driven by external market factors.
Approximately 69% of the Company’s net sales in the first six months of fiscal 2025 were generated by specialty products, compared to approximately 70% in the first six months of fiscal 2024.

The Company’s gross profit for the first six months of fiscal 2025 decreased by $19.3 million, or 7.7%, to $230.8 million from $250.1 million in the prior year fiscal period.
23

Table of Contents
This decline in the Company’s gross profit in the 2025 fiscal period was attributable to both specialty products and structural products.
82% of the Company’s gross profit in the first six months of fiscal 2025 was generated by specialty products, compared to 83% for the first six months of fiscal 2024.
The Company’s gross margin percentage was 15.5% for the 2025 fiscal period, a decrease from the 16.7% for the 2024 fiscal period.
The Company benefited in the 2025 fiscal period and the 2024 fiscal period by $2.4 million and $16.9 million (excluding interest), respectively, for changes in retroactive rates for certain anti-dumping duties, and these amounts are reflected as reductions to the Company’s Cost of products sold in the respective fiscal periods (see Note 2, Inventory, to the accompanying unaudited condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q). In the prior year fiscal period, the aforementioned $16.9 million credit to Cost of products sold was partially offset by $7.7 million (excluding interest) of expenses related to classification adjustments for certain imported goods (see Note 8, Commitments and Contingencies, to the accompanying unaudited condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q). These import duty items resulted in a net benefit of $9.1 million (excluding interest) to the Company’s Cost of products sold in the prior year fiscal period. Excluding these net benefits for import duty items from the 2025 fiscal period and the 2024 fiscal period, the Company’s gross margin percentage would have been 15.3% and 16.1%, respectively. As subsequently discussed, these items benefited the operating results for specialty products for the 2025 fiscal period and the 2024 fiscal period.
The Company was negatively impacted by an interim $2.4 million LCNRV provision in the 2024 fiscal period to adjust the carrying values of certain structural lumber and structural panel inventory items to their net realizable values as of June 29, 2024. As subsequently discussed, this item impacted the operating results for structural products in the 2024 fiscal period. Such amounts were not material for the 2025 fiscal period.

Specialty products - Net sales of specialty products, which include product types such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products, decreased by $20.5 million, or 2.0%, to $1.02 billion in the first six months of fiscal 2025.
The overall decline in net sales for specialty products in the current fiscal period was due to lower pricing for engineered wood, millwork, and specialty lumber and panels, partially offset by higher volume mainly for those same product types.
Specialty products gross profit decreased by $18.3 million, or 8.8%, to $190.1 million, due primarily to a competitive pricing environment.
Specialty products gross margin percentage decreased 140 basis points to 18.6% for the first six months of fiscal 2025 compared to 20.0% in the first six months of fiscal 2024, due primarily to a competitive pricing environment.
The net impacts of the adjustments related to duty and import matters discussed above at the Company level increased specialty products gross profit for the 2025 fiscal period and the 2024 fiscal period by $2.4 million and $9.1 million net, respectively, and increased specialty products gross margin percentage by 0.3% and 0.9% net, respectively.

Structural products - Net sales of structural products, which include product types such as lumber, plywood, oriented strand board, rebar, and remesh, increased by $15.2 million to $466.5 million in the first six months of fiscal 2025.
This overall increase in net sales for structural products was due primarily to volume increases for panels and lumber and pricing increases for lumber, partially offset by pricing declines for panels due to external market factors.
Compared to the first six months of fiscal 2024, average commodity prices in U.S. markets during the first six months of fiscal 2025 for lumber were up 15.3% and down 15.9% for panels. Higher lumber prices were driven by tightening U.S. sawmill output and dwindling import volumes.
Gross profit for structural products decreased by $1.0 million, or 2.3%, to $40.8 million from $41.7 million in the prior-year fiscal period. Higher net sales in the current year period were offset by margin compression due primarily to external market factors.
Structural products gross margin percentage for the first six months of fiscal 2025 was 8.7%, a decline from 9.2% in the prior-year fiscal period. Higher net sales in the 2025 fiscal period were offset by margin compression due primarily to external market factors.
The interim $2.4 million LCNRV provision discussed above at the Company level negatively impacted the operating results for structural products for the 2024 fiscal period. Such amounts were not material for the 2025 fiscal period.

Our SG&A expenses in the first six months of fiscal 2025 increased $8.7 million, or 4.8%, compared to the first six months of fiscal 2024. This overall increase was due primarily to increased logistics expenses driven by higher sales volumes, our strategy to grow sales in the multi-family channel, as well as expenses associated with our digital transformation.

Depreciation and amortization expense decreased $0.2 million compared to the first six months of fiscal 2024. We continue to focus on strategic capital investment.
24

Table of Contents

Other operating, net improved by $2.0 million compared to the first six months of fiscal 2024. During the first quarter of fiscal 2025, we settled certain of the initial insurance claims related to property and equipment that was damaged or destroyed at our Erwin, Tennessee owned facility in late third quarter of fiscal 2024 due to Hurricane Helene. We received insurance proceeds that exceeded the carrying values of the damaged or destroyed assets by $2.4 million, and this amount is included in Other operating, net on our unaudited condensed consolidated statement of operations for the first six months of fiscal 2024.

Interest expense, net, which includes gross interest expense less interest income, increased by $5.6 million compared to the first six months of fiscal 2024.
Gross interest expense was $24.7 million and $24.3 million in the first six months of fiscal 2025 and first six months of fiscal 2024, respectively. Gross interest expense in the first six months of fiscal 2025 and the first six months of fiscal 2024 included $0.5 million and $1.2 million, respectively, related to the aforementioned estimate for an accrual initially made and disclosed in the first quarter of 2024 related to amounts the Company believes it may owe for discrepancies in duties paid in prior years for certain imported goods (see Note 8, Commitments and Contingencies, to the unaudited condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q). Excluding these amounts, gross interest expense in the first six months of fiscal 2025 and the first six months of fiscal 2024 would have been $24.2 million and $23.1 million, respectively, an increase in the current fiscal period of $1.1 million compared to the prior year fiscal period. This $1.1 million increase in the current fiscal period was due to additional net finance leases added subsequent to the second quarter of fiscal 2024.
Interest income was $9.7 million and $14.9 million in the first six months of fiscal 2025 and first six months of fiscal 2024, respectively. Interest income in the current fiscal period and the prior year fiscal period included $0.5 million and $2.0 million, respectively, received with the aforementioned duty refunds related to changes in retroactive rates for certain anti-dumping duties (see Note 2, Inventory, to the unaudited condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q). Excluding these amounts, interest income in the current fiscal period and prior year fiscal period would have been $9.2 million and $12.9 million, respectively, a decrease of $3.7 million in the current fiscal period. This $3.7 million decrease in the current fiscal period was due to lower average balances for interest-bearing deposits of cash/cash equivalents and due to lower interest rates paid on those deposits in the current fiscal quarter.

For fiscal 2025, we currently estimate our annual effective income tax rate to be approximately 27%. Our effective income tax rates were 33.6% and 24.4% for the first six months of fiscal 2025 and the first six months of fiscal 2024, respectively. Our effective income tax rates for both periods were impacted by the permanent addback of certain nondeductible expenses, including meals and entertainment and executive compensation for the fiscal periods. Our effective income tax rate for the first six months of fiscal 2025 was also impacted by adjustments to deferred income tax assets related to stock-based compensation which increased the effective income tax rate. Our effective income tax rate for the first six months of fiscal 2024 benefited from the partial release of a state income tax valuation allowance for deferred income tax assets, which impacted only the first quarter of fiscal 2024. As noted above in the discussion and analysis for the quarterly fiscal periods, we are evaluating the potential impacts of the OBBB, but at this time, we do not expect the provisions of the OBBB to have a material impact on our effective income tax rate for fiscal 2025.

Our net income for the first six months of fiscal 2025 was $7.1 million, or $0.87 per diluted share, versus $31.8 million, or $3.66 per diluted share, in the prior-year fiscal period. Our net income for the first six months of fiscal 2025 decreased due primarily to the factors discussed above.


25

Table of Contents
Liquidity and Capital Resources

We expect our primary sources of liquidity to be cash flows from sales and operating activities in the normal course of our operations, cash and cash equivalents on hand, and availability from our revolving credit facility, as needed. We expect that these sources will be sufficient to fund our ongoing cash requirements for at least the next 12 months and into the foreseeable future. As of June 28, 2025, we had $387 million of cash and cash equivalents plus $343.5 million of availability on our revolving credit facility.

Senior Secured Notes

In October 2021, we completed the private offering of $300 million of our 6.0% senior secured notes due 2029 (the “2029 Notes”). Interest is payable semi-annually. Our 2029 Notes are scheduled to mature on November 15, 2029, and no principal is due until that time as long as we remain in compliance with the related covenants. As of June 28, 2025, we were in compliance with these covenants.

Revolving Credit Facility

Our existing revolving credit facility (“Revolving Credit Facility”) with Wells Fargo Bank, National Association, as administrative agent (“Agent”), and certain other financial institutions, matures on August 2, 2026, provided we remain in compliance with the related covenants. As of June 28, 2025, we were in compliance with such covenants.

Any outstanding borrowings under our Revolving Credit Facility bear interest at a rate per annum equal to (i) Adjusted Term Secured Overnight Financing Rate (“SOFR”) (calculated as SOFR plus 0.1%) plus a margin ranging from 1.25% to 1.75%, with the margin determined based upon average excess availability for the immediately preceding fiscal quarter for loans based on SOFR, or (ii) the Agent’s base rate (as that term is defined in the agreement for the Revolving Credit Facility) plus a margin ranging from 0.25% to 0.75%, with the margin based upon average excess availability for the immediately preceding fiscal quarter for loans based on the base rate. As of June 28, 2025, this variable interest rate for the Revolving Credit Facility was 5.32%.

Borrowings under our Revolving Credit Facility are subject to availability under the Borrowing Base (as that term is defined in the agreement for the Revolving Credit Facility). The Company is required to repay revolving loans thereunder to the extent that such revolving loans exceed the Borrowing Base then in effect. Our Revolving Credit Facility may be prepaid in whole or in part from time to time without penalty or premium but including all breakage costs incurred by any lender thereunder.

As of June 28, 2025 and December 28, 2024, we had zero outstanding borrowings under our Revolving Credit Facility and available borrowing capacity was $343.5 million and $346.2 million, respectively, net of undrawn letters of credit. Excess availability, which includes availability under our Revolving Credit Facility plus cash and cash equivalents in qualified accounts, was $730.3 million as of June 28, 2025.

Our Revolving Credit Facility is scheduled to terminate on August 2, 2026, and we intend to renew it before that date.
Finance Lease Obligations
Our finance lease obligations consist of leases for real estate, equipment, and vehicles totaling $317.6 million and $292.5 million as of June 28, 2025 and December 28, 2024, respectively. Of the $317.6 million as of June 28, 2025, $242.0 million related to real estate and $75.6 million related to equipment. Of the $292.5 million as of December 28, 2024, $242.8 million related to real estate and $49.8 million related to equipment.

Sources and Uses of Cash
Operating Activities
Net cash used in operating activities for the first six months of fiscal 2025 was $60.7 million compared to net cash provided of $4.7 million in the first six months of fiscal 2024. The $65.3 million decrease in cash generated from operating activities during the first six months of fiscal 2025 was primarily a result of a $24.7 million decrease in net income for the current fiscal period and $37.9 million of net changes in operating assets and liabilities.

Investing Activities

26

Table of Contents
Net cash used in investing activities for the first six months of fiscal 2025 was $12.9 million compared to net cash used of $11.6 million in the first six months of fiscal 2024. During the first six months of fiscal 2025 and first six months of fiscal 2024, we used cash of $15.5 million and $11.9 million, respectively, to acquire property and equipment. In the current fiscal period, we received initial insurance proceeds of $2.4 million related to property and equipment that was damaged or destroyed due to Hurricane Helene at our Erwin, Tennessee owned facility in late third quarter of fiscal 2024.

Financing Activities

Net cash used in financing activities totaled $45.3 million for the first six months of fiscal 2025 compared to net cash used of $23.4 million for the first six months of fiscal 2024. During the first six months of fiscal 2025, we used cash of $35.4 million to repurchase shares of our common stock, compared to $14.5 million for the first six months of fiscal 2024. Cash payments on finance lease obligations were higher by $1.7 million in the current fiscal period due to new finance leases added subsequent to June 29, 2024.

Common Stock Repurchases

During the first six months of fiscal 2025, we repurchased 469,129 shares of our common stock at an average price of $74.64 for a total of $35.0 million, under our 2023 stock repurchased authorization. During the first six months of fiscal 2024, we repurchased 152,403 shares of our common stock at an average price of $98.28 for a total of $15.0 million under this same authorization. These dollar amounts include broker commissions paid but exclude any excise tax that was paid or may be due on the repurchases under The Inflation Reduction Act of 2022. As of June 28, 2025, there remained $11.5 million repurchase capacity under the 2023 authorization. Between June 28, 2025 and July 25, 2025, we did not repurchase any additional shares of our common stock.

The repurchase dollar amounts noted above are based on trade date activity, while the amounts reported on our consolidated statements of cash flows for share repurchases are based on settlement date activity.

On July 28, 2025, our board of directors authorized a new share repurchase program for $50 million. The 2025 authorization may be used after exhaustion of the 2023 authorization.

Under our share repurchase program,s we may repurchase our common stock at any time or from time to time, without prior notice, subject to prevailing market conditions and other considerations. Our repurchases may be made through a variety of methods, which may include open market purchases, privately negotiated transactions, accelerated share repurchase programs, tender offers or pursuant to a trading plan that may be adopted in accordance with the Securities and Exchange Commission Rule 10b5-1.

Net Working Capital

Net working capital is an important measurement we use to determine the efficiencies of our operations and our ability to readily convert assets into cash. Net working capital is defined as the sum of accounts receivable and inventory, less accounts payable, each determined in accordance with GAAP and included in our consolidated balance sheets. This metric differs from traditional working capital in that it excludes certain current assets and current liabilities that are reported in our consolidated balance sheets. Net working capital of $492.2 million as of June 28, 2025, compared to $411.5 million as of December 28, 2024, increased on a net basis by approximately $80.7 million, as shown below:

As of
June 28, 2025December 28, 2024June 29, 2024
(In thousands)
Receivables, less allowance for doubtful accounts$278,737 $225,837 $273,537 
Inventories, net391,484 355,909 357,573 
670,221 581,746 631,110 
Accounts payable177,990 170,202 179,375 
Net working capital$492,231 $411,544 $451,735 

27

Table of Contents

Investments in Property and Equipment

Our investments in capital assets consist of purchases of owned assets and the inception of financing lease arrangements for long-lived assets. The gross value of these assets is included in property and equipment, at cost on our unaudited condensed consolidated balance sheets.

For the first six months of fiscal 2025, we invested $16.4 million in long-lived assets primarily related to investments in our fleet, facility enhancements, and ongoing digital transformation. We also added $32.9 million of property and equipment under finance leases during the first six months of fiscal 2025, primarily for new tractors and forklifts to enhance our logistics network.

For the first six months of fiscal 2024, we invested $11.9 million in long-lived assets primarily related to investments in our distribution facilities and upgrading our fleet. We also added $11.2 million in new finance leases during the 2024 fiscal quarter for new forklifts to enhance our logistics network.

Critical Accounting Policies

The preparation of our consolidated financial statements and related disclosures in conformity with GAAP requires our management to make judgments and estimates that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. There have been no material changes to our critical accounting policies and estimates from the information provided in Item 7 of our Annual Report on Form 10-K for the fiscal year ended December 28, 2024.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are exposed to certain market risks as part of our on-going business operations. Our exposure includes commodity price risk and interest rate risk. There have been no material changes to our exposure to market risks from those disclosed in our Annual Report on Form 10-K for the fiscal year ended December 28, 2024.

ITEM 4. CONTROLS AND PROCEDURES

Our management performed an evaluation, as of the end of the period covered by this report on Form 10-Q, under the supervision of our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”)). Based on that evaluation, our chief executive officer and chief financial officer have concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management including our chief executive officer and chief financial officer, to allow timely decisions regarding required disclosure.

During the period covered by this report, there have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.






28

Table of Contents
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
We are, and from time to time may be, a party to routine legal proceedings incidental to the operation of our business. Except as disclosed in Note 8, Commitments and Contingencies, under Regulatory Matters, to our unaudited condensed consolidated financial statements in this Quarterly Report on Form 10-Q, the Company does not expect that the outcome of any other pending or threatened proceedings, if determined adversely to the Company, would individually, or taken together, have a material adverse effect on our financial condition, operating results, or cash flows, based on our current understanding of the relevant facts. Legal expenses incurred related to these contingencies are generally expensed as incurred.
ITEM 1A. RISK FACTORS
There have been no material changes to the risk factors disclosed in Part I, Item 1A, “Risk Factors," in the Company’s Annual Report on Form 10-K for the year ended December 28, 2024, as supplemented in Part II, Item 1A, “Risk Factors,” in the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 29, 2025.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
The following table presents our share repurchase activity for each fiscal month of the fiscal quarter ended June 28, 2025:


Period
Total Number of Shares Purchased (1)
Average Price Paid per Share(2)
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (3)
Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs
March 30 - May 3180,021 $71.44 180,000 $18,622,443 
May 4 - May 31103,081 $69.37 103,081 $11,475,065 
June 1 - June 2818,305 $67.89 — $11,475,065 
Total301,407 283,081 

(1) Includes shares withheld by us in connection with tax withholding obligations of our employees upon vesting of such employees’ restricted stock unit awards.

(2) Includes broker commissions associated with the repurchases. Excludes federal excise tax incurred under The Inflation Reduction Act of 2022.

(3) On October 31, 2023, our Board of Directors announced a new share repurchase authorization for up to $100 million. As of June 28, 2025, we had a remaining authorization amount of approximately $11.5 million under this program. With the remaining availability under the stock repurchase program, we may repurchase our common stock at any time or from time to time, without prior notice, subject to prevailing market conditions and other considerations. Our repurchases may be made through a variety of methods, which may include open market purchases, privately negotiated transactions, accelerated share repurchase programs, tender offers or pursuant to a trading plan that may be adopted in accordance with the Securities and Exchange Commission Rule 10b5-1.


On July 28, 2025, our board of directors authorized a new share repurchase program for $50 million that may used after exhaustion of the 2023 authorization. Under this new authorization, we may repurchase our common stock at any time or from time to time, without prior notice, subject to prevailing market conditions and other considerations. Our repurchases may be made through a variety of methods, which may include open market purchases, privately negotiated transactions, accelerated share repurchase programs, tender offers or pursuant to a trading plan that may be adopted in accordance with the Securities and Exchange Commission Rule 10b5-1.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
29

Table of Contents
ITEM 5. OTHER INFORMATION
None of our directors or executive officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the second quarter of fiscal 2025.
30

Table of Contents
ITEM 6. EXHIBITS
Exhibit
Number
Description
10.1
Employment Agreement by and among BlueLinx Corporation, BlueLinx Holdings Inc., and C. Kelly Wall, dated May 12, 2025 (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the Securities and Exchange Commission on May 13, 2025) ±
10.2
*
Form of 2025 Director Restricted Stock Unit Award Agreement under the BlueLinx Holdings Inc. 2021 Amended and Restated Long-Term Incentive Plan ±
10.3
*
Form of 2025 Employee Time-Based Restricted Stock Unit Award Agreement under the BlueLinx Holdings Inc. 2021 Amended and Restated Long-Term Incentive Plan ±
10.4
Form of 2025 Employee Performance-Based Restricted Stock Unit Award Agreement (TSR) under the BlueLinx Holdings Inc. 2021 Amended and Restated Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the Securities and Exchange Commission on June 11, 2025) ±
31.1
*
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2
*
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1
**
Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2
**
Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.DefDefinition Linkbase Document.
101.PrePresentation Linkbase Document.
101.LabLabels Linkbase Document.
101.CalCalculation Linkbase Document.
101.SchSchema Document.
101.InsInstance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
104
The cover page from this Quarterly Report on Form 10-Q for the quarter ended June 28, 2025, formatted in Inline XBRL.
*Filed herewith.
**Exhibit is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended.
±Indicates management contract or compensatory plan or arrangement.

31

Table of Contents
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
   
  BlueLinx Holdings Inc.
  (Registrant)
   
Date: July 29, 2025By:/s/ Shyam K. Reddy
 Shyam K. Reddy
 President and Chief Executive Officer
(Principal Executive Officer)
Date: July 29, 2025By:/s/ C. Kelly Wall
C. Kelly Wall
Senior Vice President, Chief Financial Officer and Treasurer
(Principal Financial Officer)
Date: July 29, 2025By:/s/ Kimberly A. DeBrock
Kimberly A. DeBrock
Vice President and Chief Accounting Officer
(Principal Accounting Officer)
 

32

FAQ

What drove KNSA's 44% revenue growth in Q2 2025?

Higher U.S. demand for ARCALYST increased product revenue to $156.8 m versus $103.4 m a year earlier.

Did Kiniksa post a profit in the latest quarter?

Yes. Q2 2025 net income was $17.8 m (diluted EPS $0.23), a reversal from a $3.9 m loss in Q2 2024.

How much cash does KNSA have after Q2 2025?

Cash, cash equivalents and U.S.-Treasury investments totaled $307.8 m as of 30 Jun 2025.

What is the impact of terminating the mavrilimumab deal with Huadong?

The April 2025 termination eliminates up to $576 m potential milestones and royalties linked to mavrilimumab in Asia-Pacific.

What milestone opportunities remain for Kiniksa?

The Genentech vixarelimab deal still carries $570 m in potential milestones; ARCALYST could add $50 m from Huadong sales milestones.

Is the company adequately funded?

Management states existing $307.8 m liquidity is sufficient to fund operations for at least 12 months.
Bluelinx Hldgs Inc

NYSE:BXC

BXC Rankings

BXC Latest News

BXC Latest SEC Filings

BXC Stock Data

582.30M
7.66M
4.16%
94.89%
2.16%
Industrial Distribution
Wholesale-lumber, Plywood, Millwork & Wood Panels
Link
United States
MARIETTA